<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001217" GROUP_ID="COLOCA" ID="868599081713460311" MERGED_FROM="" MODIFIED="2008-07-24 16:09:13 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Short title (no longer in use): Thromboprophylaxis in colorectal surgery&lt;/p&gt;&lt;p&gt;&lt;br&gt;Old title: Heparins and mechanical methods for thromboprophylaxis in colorectal surgery&lt;/p&gt;" NOTES_MODIFIED="2008-07-24 16:09:13 +0200" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="002" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.2">
<COVER_SHEET MODIFIED="2008-07-24 16:04:26 +0200" MODIFIED_BY="Henning Keinke Andersen">
<TITLE>Heparins and mechanical methods for thromboprophylaxis in colorectal surgery</TITLE>
<CONTACT>
<PERSON ID="6565" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Peer</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wille-Jørgensen</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Surgeon</POSITION>
<EMAIL_1>pwj01@bbh.regionh.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Surgical Gastroenterology K</DEPARTMENT>
<ORGANISATION>Bispebjerg Hospital</ORGANISATION>
<ADDRESS_1>Bispebjerg Bakke 23</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen NV</CITY>
<ZIP>DK-2400</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3531 3086</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-07-24 16:04:26 +0200" MODIFIED_BY="Henning Keinke Andersen">
<PERSON ID="6565" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Peer</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Wille-Jørgensen</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant Surgeon</POSITION>
<EMAIL_1>pwj01@bbh.regionh.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Surgical Gastroenterology K</DEPARTMENT>
<ORGANISATION>Bispebjerg Hospital</ORGANISATION>
<ADDRESS_1>Bispebjerg Bakke 23</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen NV</CITY>
<ZIP>DK-2400</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3531 3086</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12874" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Morten Schnack</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rasmussen</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Registrar</POSITION>
<EMAIL_1>msr@dadlnet.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Surgical gastroenterology dept. K</DEPARTMENT>
<ORGANISATION>H:S Bispebjerg Hospital</ORGANISATION>
<ADDRESS_1>23 Bispebjeg Bakke</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK 2400</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12801" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Betina Ristorp</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Andersen</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ktbr@post6.tele.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT>
<ORGANISATION>Hillerød University Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Hillerød</CITY>
<ZIP>3400</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17890" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Lars</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Borly</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>lars.borly@mobilixnet.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Obstetrics and Gynecology</DEPARTMENT>
<ORGANISATION>Næstved University Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Næstved</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-07-23 16:26:36 +0200" MODIFIED_BY="Henning Keinke Andersen" NOTES="&lt;p&gt;Minor update: 20/11/03&lt;/p&gt;&lt;p&gt;New studies sought but none found: 30/04/03&lt;/p&gt;&lt;p&gt;Reformatted: 17/08/99&lt;/p&gt;" NOTES_MODIFIED="2008-07-23 16:26:36 +0200" NOTES_MODIFIED_BY="Henning Keinke Andersen">
<UP_TO_DATE>
<DATE DAY="28" MONTH="8" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="4" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="9" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW NOTES="&lt;p&gt;Review title changed in agreement with author (19/8/99)&lt;br&gt;New co-author, Lars Borly (24/8/99)&lt;br&gt;Revised after peer-reviewing (8/1/2001)&lt;br&gt;The reference McLeod 2001 substitutes the former abstract McLeod 1997. &lt;br&gt;Updated (01/09/2003)&lt;/p&gt;">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="23" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="28" MONTH="8" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>H:S Central Research Fund</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>A combination of graduated compression stockings and heparin seems to be the optimal prophylaxis for patients undergoing colorectal surgery.</TITLE>
<SUMMARY_BODY>
<P>Patients undergoing surgery of the large bowel and the rectum have a considerable risk of developing vascular complications expressed as venous thrombosis and/or thrombosis in the lungs (pulmonary embolism). These complications can lead to lifelong impaired venous function in the legs or occasionally sudden postoperative death. In order to avoid these complications, patients are often treated with blood-thinning medicine (anticoagulation) and graded compression stockings during operation. A combination treatment of Heparin and TED-stockings have been proved effective in general surgery. This review demonstrates that this combined treatment also is effective within the high-risk group of patients undergoing surgery of the large bowel or rectum.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Colorectal surgery implies higher risk of postoperative thromboembolic complications as deep venous thrombosis (DVT) and pulmonary embolism (PE) than general surgery. The best prophylaxis in general surgery is heparin and graded compression stockings. No systematic review on combination prophylaxis or on thrombosis prophylaxis in colorectal surgery has been published.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare the incidence of postoperative thromboembolism after colorectal surgery using prophylactic methods focussing on heparins and mechanical methods alone and in combinations.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Electronic searches was performed in PUBMED, EMBASE, LILACS and the Cochrane Library. Abstract books from major congresses were handsearched as were reference lists from previously performed reviews.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>RCT or CCT comparing prophylactic interventions and/or placebo. Outcomes were ascending venography, 125 I-fibrinogen uptake test, ultrasound methods, pulmonary scintigraphy. Studies, using thermographic methods, other isotopic methods, plethysmographic methods, and purely clinical methods as the only diagnostic measure were excluded. 558 studies were identified - 477 were excluded. Only 3 of the identified studies focused exclusively on colorectal surgery. Studies of general surgery contain considerable numbers of colorectal patients. The authors of 66 studies in general and/or abdominal surgery were contacted for retrieving the results from the colorectal patients. Answers were received from very few. 19 studies entered this review.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>All studies and all data extraction were performed by at least two of the authors. Outcome was deep venous thrombosis and/or pulmonary embolism. Analysis of bleeding complications were unfeasible. 12 meaningful outcomes were analysed by means of the fixed effects model with Peto Odds Ratios.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Heparins versus no treatment: Any kind of heparincompared to no treatment or placebo (comparison 07.03, 11 studies). Heparin is better in preventing DVT and/or PE with a Peto Odds ratio at 0.32 (95% Confidence Interval 0.20-0.53) <BR/>Unfractionated heparin versus low molecular weight heparin (comparison 08.03, 4 studies). The two treatments were found equally effective in preventing DVT and/or PE with a Peto Odds ratio 1.01 (95% Confidence Interval 0.67-1.52).<BR/>Mechanical methods (comparison 10.3, 2 studies).The combination of graded compression stockings and LDH is better than LDH alone in preventing DVT and/or PE with a Peto Odds ratio at 4.17 (95% Confidence Interval 1.37-12.70).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The optimal prophylaxis in colorectal surgery is the combination of graduated compression stockings and low-dose unfractionated heparin. The unfractionated heparin can be replaced with low molecular weight heparin.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Colorectal surgery implies a specific high risk for postoperative thromboembolic complications (TE) in form of deep venous thrombosis (DVT) and pulmonary embolism (PE) as compared to general surgery (<LINK REF="REF-Wille_x002d_J_x00f8_rgensen-1988" TYPE="REFERENCE">Wille-Jørgensen 1988</LINK>, <LINK REF="STD-Torngren-1982" TYPE="STUDY">Torngren 1982</LINK>, <LINK REF="REF-Wille_x002d_J_x00f8_rgensen-1990" TYPE="REFERENCE">Wille-Jørgensen 1990</LINK>, <LINK REF="REF-Kjaergaard-1985" TYPE="REFERENCE">Kjaergaard 1985</LINK>). The reason for this is unknown. Pelvic dissection and/ or the peroperative positioning of the patients has been suggested. The different types of prophylaxis have been very well documented both in respect of many RCT´s and in systematic and unsystematic reviews (<LINK REF="REF-Collins-et-al-1988" TYPE="REFERENCE">Collins et al 1988</LINK>, <LINK REF="REF-Clagett-1988" TYPE="REFERENCE">Clagett 1988</LINK>, <LINK REF="STD-Wille_x002d_J_x00f8_rgensen-1991" TYPE="STUDY">Wille-Jørgensen 1991</LINK>, <LINK REF="REF-Leizorovicz-1992" TYPE="REFERENCE">Leizorovicz 1992</LINK>, <LINK REF="REF-Nurmohammed-1992" TYPE="REFERENCE">Nurmohammed 1992</LINK>, <LINK REF="REF-J_x00f8_rgensen--1993" TYPE="REFERENCE">Jørgensen 1993</LINK>, <LINK REF="REF-Clagett--1995" TYPE="REFERENCE">Clagett 1995</LINK>). Most of these reviews have dealt with the efficacy of various forms of heparin, and the overall conclusions are that low molecular weight heparin (LMWH) is an effective form of prophylaxis and perhaps better than unfractionated heparin. The latter question is addressed in a current Cochrane Review Protocol (<LINK REF="REF-Leizorovicz--1997" TYPE="REFERENCE">Leizorovicz 1997</LINK>). One investigation indicates, that a better prophylaxis can be obtained in patients with malignant disease, using a higher dose of LMWH (<LINK REF="STD-Bergqvist-1995" TYPE="STUDY">Bergqvist 1995</LINK>). Mechanical compression in forms of graded compression stockings and/or intermittent compression devices are effective (<LINK REF="STD-Wille_x002d_J_x00f8_rgensen-1991" TYPE="STUDY">Wille-Jørgensen 1991</LINK>), and a systematic Cochrane Review on the efficacy of graded compression stockings in all kind of surgery has recently been included in The Cochrane Library (<LINK REF="REF-Amarigiri-2000" TYPE="REFERENCE">Amarigiri 2000</LINK>). A better prophylaxis can be obtained by the use of a combination of medical and mechanical prophylaxis (<LINK REF="STD-Wille_x002d_J_x00f8_rgensen-1991" TYPE="STUDY">Wille-Jørgensen 1991</LINK>). The use of this combination has not yet been subject to a systematic review as well as a systematic review never previously addressed the problems with thromboprophylaxis in the group of patients undergoing colorectal surgery.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the incidence of postoperative thromboembolism after colorectal surgery having used different prophylactic methods focussing on various heparins and heparanoids and mechanical methods and their combinations.<BR/>It was the plan to stratify the studies in pre- or postoperative start of prophylaxis, but due to few studies this was not possible.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>RCT or CCT comparing minimum two of the mentioned prophylactic interventions and/or placebo. The randomizations should have taken place before start of treatment. As diagnostic measures ascending venography, 125 I-fibrinogen uptake test, ultrasound/doppler methods, pulmonary scintigraphy, or autopsy should have been used for the whole population. Studies, using thermographic methods, other isotopic methods than the 125 I-fibrinogen uptake test, plethysmographic methods, and purely clinical methods as the only diagnostic measure have been excluded.<BR/>As expected only few of the identified studies exclusively focused on colorectal surgery. On the other hand most of the studies in general surgery contain a considerable number of patients having colorectal surgery performed. The primary authors and/or the sponsoring pharmaceutical companies of studies in general and/or abdominal surgery were contacted in order to make them report the results from the colorectal patients exclusively. <BR/>The start and end (in time) of the prophylaxis must have been stated</P>
<P>The studies should have described the mortality within 30 days. If this information is not available, it was sought directly from authors, but was very seldom obtained.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients undergoing major colorectal surgery for cancer or benign diseases. The participants had to be over 18 years of age. Major surgery implied:<BR/>Resections with or without anastomosis, diverting stomas. Excluded were endoscopic and/or transanal procedures.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>A: Unfractionated heparin (5000 IU b.i.d. or t.i.d)<BR/>B: Low-molecular weight heparins in different doses<BR/>C: Any kind of heparin + graded compression stockings<BR/>D: Any kind of heparin + Intermittent pneumatic compression<BR/>E: Intermittent compression alone<BR/>F: Placebo or untreated</P>
<P>The comparisons are listed in the tables of comparisons section </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The outcome was either DVT, PE, fatal PE or total mortality, evaluated within a standardized postoperative time (preferably 30 days for mortality and 7-14 days for DVT/PE).<BR/>The TE were diagnosed in an objective way using either mandatory venography, 125I-fibrinogen-uptake test, or Doppler-ultrasound, pulmonary perfusion/ventilation scans and/or autopsy. <BR/>The evaluations of the outcomes should at least be blinded against the prophylactic treatment given (assessor-blinding), if a double-blind method was not used.<BR/>It was the intention to include both intention to treat analyses and fulfilled protocol analysis. Due to the collected data, we were only able to perform the latter.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: Collaborative review group search strategy: <BR/>Electronic searches goes back to 1966 (in PUBMED, 1967 in LILACS and 1980 in EMBASE). The general search strategy, described by the Cochrane Colorectal Cancer Group was used in MEDLINE and The Cochrane Library as well as a comparable search strategy in EMBASE-search. A search for randomised clinical trials (RCT) and controlled clinical trials (CCT) was done. The specialised search used the terms:</P>
<P>colorectal or<BR/>colonic or<BR/>rectal or <BR/>general surgery or<BR/>abdominal surgery </P>
<P>and</P>
<P>thrombos* or thromboem*<BR/>and</P>
<P>prophylaxis or prevention <BR/>The electronic searches searched up to May 2003.</P>
<P>In order to identify more studies, the personal bibliographic register belonging to Peer Wille-Jørgensen, Denmark, was hand searched. The reference-lists form major review articles from 1990 were scrutinized. All references from previously performed meta-analyses were crossed-checked with the other searches . The abstract books of the Congresses arranged by The International Society on Thrombosis and Haemostasis as well as The Mediterrenean League aganist Thrombosis were consulted back to 1976.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>All identified trials were reviewed independently by two authors in order to validate the scientific approach and to evaluate, whether the trial could be included. Following data were extracted by minimum two authors: Type of prophylaxis, type of endpoint (DVT, PE, TE, and fatal PE), bleeding listed as major and minor bleeding events, bleeding in ml, per- and postoperative transfusion requirements. The definition of major and minor bleeding events followed the individual authors.<BR/>If both authors disagreed on study-validity and/or data extraction consensus was obtained. This happened in two occasions. The bleeding episodes were so inhomogeneous described that it was not possible to relate these complications to the colorectal patients. An analysis of bleeding exclusively on colorectal patients was thus omitted.</P>
<P>The authors of trials on general surgery were contacted by "snail-mail" and E-mail (if possible) in order to stratify their individual trial results in colorectal surgery and other surgery. </P>
<P>Following pharmaceutical companies were asked for the colorectal data from the studies on general surgery and abdominal surgery.</P>
<P>- Leo Chemicals (Denmark) (tinzaparine)<BR/>- Pharmacia (Sweden) (dalteparine)<BR/>- Aventis (France, USA) (enoxaparine)<BR/>- Choay (France) (fraxiparine)<BR/>- Alfa (Italy) (Fluxum)<BR/>- Knoll (Germany) (reviparine)</P>
<P>The process of getting the colorectal data out of the studies describing general surgery was extremely slow with a very modest outcome. It was thus decided to finish the review with the results obtained. Studies from which the results after colorectal surgery could not be obtained were not excluded, but placed in the category: Studies awaiting assessment, giving the authors an extra chance to answer our requests. </P>
<P>The results from each trial were entered into the RevMan 4.1 module and analysed as binomial data for the thromboembolic endpoints. We used the fixed effects model for the metaanalyses. When performing the analyses studies, different types of low-molecular weight heparins were only entered into the same analysis if the dose of LMWH was judged to be comparable in anti-Xa units (20 mg enoxaparine equalize 2500 anti-Xa units) and presuming the control groups were uniform. <BR/>In studies evaluating the efficacy of mechanical prophylaxis, medical prophylaxis (or none) should be the same in both the treated group and the control group within one study, but could vary between studies.</P>
<P>It was allowed, that the type of diagnostic objective measures differed across trials, as long as it was uniformly applied within the individual study to all patients.</P>
<P>As it is known, that there is a great interobserver variation in the evaluation of the endpoints used in prophylactic trials, which substantially can influence the incidence of TE (<LINK REF="REF-Wille_x002d_J_x00f8_rgensen-1992" TYPE="REFERENCE">Wille-Jørgensen 1992</LINK>), no comparisons across trials between apparently equal groups from different trials were thus made (e.g.. The incidence of DVT after two different LMWH´s in two different studies with apparently equal control groups and diagnostics)</P>
<P>The trials were checked for heterogeneity, when performing the analyses.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>The electronic searches and the handsearch revealed 558 studies. Of these 464 were excluded by the primary selection because they did not include colorectal patients, did not address prophylaxis, were not RCT or CCT, or obviously represented double publications of RCT. Fifteen other studies were excluded in the second round due to various reasons listed in the list of excluded studies. In 66 occasions primary authors and/or sponsoring pharmaceutical companies were contacted in order to obtain the colorectal data. This process was only successful in 4 cases, despite several reminders and personal contacts. No authors directly stated that they did not want to give the information, in three cases the authors stated that the data were lost. Studies from which the results after colorectal surgery could not be obtained were not excluded, but placed in the category: Studies awaiting assessment, giving the authors an extra chance to answer our requests. In 19 studies data were useable. <U>
<BR/>
</U>
<BR/>In three studies the material consisted of colorectal patients only (<LINK REF="STD-Ho-1999" TYPE="STUDY">Ho 1999</LINK>, <LINK REF="STD-Mcleod-2001" TYPE="STUDY">Mcleod 2001</LINK>, <LINK REF="STD-Wille_x002d_J_x00f8_rgensen-1986" TYPE="STUDY">Wille-Jørgensen 1986</LINK>), while colorectal data were extracted from 16 studies. The bleeding episodes for colorectal patients only could be defined in two studies (<LINK REF="STD-Ho-1999" TYPE="STUDY">Ho 1999</LINK>, <LINK REF="STD-Mcleod-2001" TYPE="STUDY">Mcleod 2001</LINK>). Ten studies tested any kind of heparin versus no treatment or placebo in a total of 641 patients. Four studies tested unfractionated heparin versus LMWH in a total of 1183 patients and four studies investigated mechanical methods in various combinations in a total of 130 patients.</P>
<P>In 15 studies the 125I-fibrinogen uptake test was the primary screening method for DVT, supplied with confirmatory venography in 5 studies. Mandatory venography was used in one (the largest) study (<LINK REF="STD-Mcleod-2001" TYPE="STUDY">Mcleod 2001</LINK>) while Doppler-ultrasound was used in three studies. The number of PE was listed in only 4 studies, all based on clinical suspicion. Total mortality was mentioned in two studies and 30 days follow up was available in two studies. No studies described the autopsy frequency.</P>
<P>Details of the individual studies are listed in table of included studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Demographic data were described sufficiently and equally balanced between treatment groups of colorectal cancer patients in three studies only (<LINK REF="STD-Ho-1999" TYPE="STUDY">Ho 1999</LINK>, <LINK REF="STD-Wille_x002d_J_x00f8_rgensen-1986" TYPE="STUDY">Wille-Jørgensen 1986</LINK>, <LINK REF="STD-Mcleod-2001" TYPE="STUDY">Mcleod 2001</LINK>). </P>
<P>Seven of the 19 studies used a double-blind design, three other studies were assessor-blinded - in the remaining nine studies blinding was not documented/adressed in the report. Allocation concealment was judged adequate in 10 studies and unclear in nine. Only three studies included a modified intention to treat analysis, reporting all patients with a primary outcome, irrespectivly of treatment received.</P>
<P>Details of the individual studies are listed in table of included studies.</P>
<P>No effort was done in order to rank the studies according to methodological quality.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>The total material gave opportunity to perform 12 different meaningful comparisons. The most important are highlighted in this text session. The detailed analyses can be studied in metaview.</P>
<P>Heparins versus no treatment:<BR/>Unfractionated heparin (LDH) gives a better prophylaxis against DVT and/or PE than does no treatment or placebo (comparison 03.03, 8 studies, 292 patients) with an overall Peto Odds Ratio at 0.35 (95% Confidence Interval 0.20-0.62) with no significant heterogeneity in the analyses. Also low molecular weight heparin (LMWH) seems better than no treatment or placebo in preventing DVT (Peto Odds ratio 0.17 (95% Confidence Interval 0.05-0.54)(comparison 06.01, 3 studies, 349 patients). <BR/>When any kind of heparin is compared to no treatment or placebo (comparison 07.03, 11 studies, 641 patients) heparin is better in preventing DVT and/or PE with a Peto Odds ratio at 0.32 (95% Confidence Interval 0.20-0.53) with no significant heterogeneity in the analyses.</P>
<P>LDH versus LMWH:<BR/>Four studies addressed this question (comparison 08.03, 1183 patients) and the two treatments were found equally effective in preventing DVT and/or PE (Peto Odds ratio 1.01 (95% Confidence Interval 0.67-1.52).</P>
<P>Mechanical methods:<BR/>There was not sufficient data to evaluate intermittent pneumatic compression or graded compression stockings (comparison 09.01, 11.01, and 12.01) neither against no treatment nor heparin.<BR/>The combination of graded compression stockings and LDH is better than LDH alone in preventing DVT and/or PE (comparison 10.3, 2 studies, 111 patients) (observe inverse analysis)) with a Peto Odds ratio at 4.17 (95% Confidence Interval 1.37-12.70). </P>
<P>The data on PE alone as outcome parameter were too sparse to draw any conclusions.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>During the performance of this review, the primary protocol was violated several times due to unexpected distribution of and limited access to data. The violations were: <BR/>- doppler-ultrasound was permitted as screening parameter, as it was considered that the limited sensitivity of this type of investigation in asymptomatic patients (<LINK REF="REF-Mantoni-1997" TYPE="REFERENCE">Mantoni 1997</LINK>, <LINK REF="REF-Dauzat-1997" TYPE="REFERENCE">Dauzat 1997</LINK>) was equally distributed among the randomised groups.<BR/>- neiher analysis of total mortality and/or fatal PE nor intention to treat analyses were performed due to lack of data.<BR/>- some non-blinded studies were included.<BR/>No analyses of bleeding complications due to heterogeneity between the method of computing and the fact, that the data were unaccessible for colorectal patients in most studies, thus loosing the ability to balance between efficacy and safety.</P>
<P>These violations of the protocol might invalidate this review. Some studies not fulfilling the original selection criteria were included, as the overall scientific methodology were judged to be reasonable free of bias, and the results were considered to important to leave out. If we have followed the original crieteria for selection only 10 studies had been included, but the overall results and conclusions would not have been altered.</P>
<P>When evaluating the efficacy of thromboprophylaxis it has been a methodological demand to screen all patients with an objective method as most postoperative TE are asymptomatic. One could argue, that this is evaluating a treatment with a surrogate parameters, as the individual patient do not care, whether he/she experience an asymptomatic TE. The most relevant endpoint would be symptomatic DVT and/or PE, perhaps even fatal PE and/or total mortality. This would demand very large trials (up to 50,000 in each treatment arm), but feasible in a multi centre setup. The largest thromboprophylactic trial ever performed is to our knowledge German and showed that the incidence of fatal PE and total mortality was the same after prophylaxis with either unfractionated heparin or LMWH (<LINK REF="REF-Haas-1999" TYPE="REFERENCE">Haas 1999</LINK>). There is although a proportionality between the incidence of fatal PE and asymptomatic TE (<LINK REF="STD-Wille_x002d_J_x00f8_rgensen-1991" TYPE="STUDY">Wille-Jørgensen 1991</LINK>), and it is shown that venous function often is impaired after even asymptomatic DVT, giving rise to chronic venous insufficiency (<LINK REF="REF-Siragusa-1997" TYPE="REFERENCE">Siragusa 1997</LINK>, <LINK REF="REF-Andersen-1991" TYPE="REFERENCE">Andersen 1991</LINK>). Although not optimal, studies using sensitive screening methods can in our opinion be used in evaluating the efficacy of various prophylactic methods.</P>
<P>There was no significant statistical heterogeneity among the studies, but the meta-analysis performed on all heparins versus no treatment or placebo (comparison 07) should be taken with some reserve, due to methodological heterogeneity between the studies. Also one should account for the different drugs and control groups being used in this analysis. As 10 out of 11 studies point in the same direction the conclusion that heparin works is although considered valid.</P>
<P>The analyses are invalidated by the many missing data, as we were unable to retrieve data of colorectal patients from the primary authors but the results obtained are in agreement with other reviews dealing with general surgery as a whole (<LINK REF="STD-Wille_x002d_J_x00f8_rgensen-1991" TYPE="STUDY">Wille-Jørgensen 1991</LINK>) except for one point. We were not able to find any difference between LMWH and LDH. Nurmohammed (<LINK REF="REF-Nurmohammed-1992" TYPE="REFERENCE">Nurmohammed 1992</LINK>) found LMWH to be more effective in orthopaedic surgery but not convincingly in general surgery a comprehensive meta-analysis. This analysis is although to be taken with care due to severe heterogeneity. In a systematic review where meta-analysis was omitted due to the heterogeneity (<LINK REF="REF-J_x00f8_rgensen--1993" TYPE="REFERENCE">Jørgensen 1993</LINK>), it was concluded that the two treatments do not differ substantially. The efforts in retrieving the inaccessible data will continue and this review will be updated whenever new data on colorectal patients are at hand. </P>
<P>In the investigations with the combination regimens (<LINK REF="STD-Wille_x002d_J_x00f8_rgensen-1986" TYPE="STUDY">Wille-Jørgensen 1986</LINK>, <LINK REF="REF-Wille_x002d_Jorgensen-1991" TYPE="REFERENCE">Wille-Jorgensen 1991</LINK>) unfractionated heparin was used. There are no investigations in general surgery where the combination of LMWH and stockings has been investigated, but there is no reason to believe that different results would be obtained, if the unfractionated heparin was replaced by LMWH in the combination regimens. The combination regimen seems to be the best, but there are limited data available and the data all come the same author. An investigation in general surgery using a paired design with stockings on one leg only (randomised to left or right), thus comparing legs and not persons also showed a significant better effect of the combination as compared with unfractionated heparin alone (<LINK REF="STD-T_x00f6_rngren-1980" TYPE="STUDY">Törngren 1980</LINK>). Due to the design this study was not included in the analysis, but the result supports our conclusion. Two of the studies awaiting assessment investigates the combination therapy (<LINK REF="STD-Borow-1983" TYPE="STUDY">Borow 1983</LINK>, <LINK REF="STD-Moser-1976" TYPE="STUDY">Moser 1976</LINK>). The first find a significant better effect of the combination as compared to heparin alone and the latter could not show any significance in a small sample size. Although these missing data comprise a publication bias, this is not considered to alter the conclusion.</P>
<P>There are other ways to prevent postoperative DVT and/or PE than heparins and stockings. Aspirin has during the last couple of years been shown to be somewhat effective (<LINK REF="REF-Collaborative-1994" TYPE="REFERENCE">Collaborative 1994</LINK>), but seemingly not as effective as heparins. No valid comparisons have to our knowledge been made between aspirin and heparins. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Both unfractionated heparin and low molecular weight heparin can be used as effective prophylaxis against postoperative thromboembolic complications after colorectal surgery. The optimal prophylaxis in colorectal surgery seems to be the combination of graded compression stockings and low-dose unfractionated heparin. The unfractionated heparin can likely be replaced with low molecular weight heparin.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further effort to retrieve colorectal results from the many studies on general surgery should be continued. Large randomised trials evaluating the use of the combination regime versus monotherapy with fatal pulmonary embolism as outcome should be performed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The few primary authors (<LINK REF="STD-Maressi-1993" TYPE="STUDY">Maressi 1993</LINK>, <LINK REF="STD-Onarheim-1986" TYPE="STUDY">Onarheim 1986</LINK>) who supplied us with original data are greatly acknowledged.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>One of the reviewers (Morten Schnack Rasmussen) was part time during the review process working as a research fellow on longterm thrombosis prophylaxis. His salary was partly paid for by Pharmacia/Upjohn - a company which produces one of the compounds, which potentially occur in this review. The current review has no connection to his work as a research fellow, despite being in the same scientific area. The company had no influence on the review. No conflict of interest is considered to exist in this respect.<BR/>The three other reviewers have no economical connection to the pharmaceutical industry with respect to this review, thus no conflict of interest exists.<BR/>The primary reviewer has two papers included in the analyses.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Peer Wille-Jørgensen came with the idea, structured the work, extracted data and made the final manuscript. Bettina R. Andersen and Morten S. Rasmussen did the literature-search and extracted data. Lars Borly retrieved extra data from authors, made the data-entry, and the analysis. Morten S. Rasmussen and Lisbeth S. G. Mathiesen did the literature search and latest update. Peer Wille-Jørgensen did the final editing work.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Butson-1981" NAME="Butson 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Butson AR</AU>
<TI>Intermittent pneumatic calf compression for prevention of deep venous thrombosis in general abdominal surgery</TI>
<SO>Am J Surg</SO>
<YR>1981</YR>
<VL>142</VL>
<NO>2</NO>
<PG>525-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="82021671"/>
<IDENTIFIER TYPE="OTHER" VALUE="1254"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Covey-1975" NAME="Covey 1975" YEAR="1975">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Covey TH, Sherman L, Baue AE</AU>
<TI>Low-dose heparin in postoperative patients: a prospective, coded study</TI>
<SO>Arch Surg</SO>
<YR>1975</YR>
<VL>110</VL>
<PG>1021-1026</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="525"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fricker-1988" NAME="Fricker 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fricker JP, Vergnes Y, Schach R, Heitz A, Eber M, Grunebaum L et al</AU>
<TI>Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery</TI>
<SO>Eur J Clin Invest</SO>
<YR>1988</YR>
<VL>18</VL>
<NO>6</NO>
<PG>561-567</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89137198"/>
<IDENTIFIER TYPE="OTHER" VALUE="176"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallus-1976" NAME="Gallus 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gallus AS, Hirsh J, O'Brien SE, McBride JA, Tuttle RJ, Gent M</AU>
<TI>Prevention of venous thrombosis with small, subcutaneous doses of heparin</TI>
<SO>JAMA</SO>
<YR>1976</YR>
<VL>235</VL>
<PG>1980-1982</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="526"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ho-1999" NAME="Ho 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ho YH, Seow-Choen F, Leong A, Eu KW, Nyam D, Teoh MK</AU>
<TI>Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients</TI>
<SO>Dis Colon Rectum</SO>
<YR>1999</YR>
<VL>42</VL>
<PG>196-203</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="524"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joffe-1976" NAME="Joffe 1976" YEAR="1976">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Joffe S</AU>
<TI>Drug prevention of postoperative deep vein thrombosis. A compararative study of calcium heparinate and sodium pentosan polysulfate</TI>
<SO>Arch Surg</SO>
<YR>1976</YR>
<VL>111</VL>
<PG>37-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="527"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koppenhagen-1992" NAME="Koppenhagen 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koppenhagen K, Adolf J, Matthes M, Troster E, Roder JD, Hass S et al</AU>
<TI>Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery</TI>
<SO>Thromb Haemost</SO>
<YR>1992</YR>
<VL>67</VL>
<NO>6</NO>
<PG>627-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92376750"/>
<IDENTIFIER TYPE="OTHER" VALUE="274"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosir-1996" NAME="Kosir 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kosir MA, Kozol RA, Perales A, McGee K, Beleski K, Lange P et al</AU>
<TI>Is DVT prophylaxis overemphasized? A randomized prospective study</TI>
<SO>J-Surg-Res</SO>
<YR>1996</YR>
<VL>60</VL>
<PG>289-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CN-00006333 - CCTR. MEDLINE 96173505 EMBASE 96068622"/>
<IDENTIFIER TYPE="OTHER" VALUE="277"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lahnborg-1974" NAME="Lahnborg 1974" YEAR="1974">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lahnborg G, Bergstrom K, Friman L, Lagergren H</AU>
<TI>Effect of low-dose heparin on incidence of postoperative pulmonary embolism detected by photoscanning</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>1</VL>
<PG>329-331</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="528"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Maressi-1993" NAME="Maressi 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Maressi A, Balzano G, Mari G, D´Angelo SV, Valle PD, Di Carlo V et al</AU>
<TI>Prevention of Postoperative Deep Vein Thrombosis in Cancer Patients. A Randomized Trial with Low Molecular Weight Heparin (CY 216)</TI>
<SO>Int Surg</SO>
<YR>1993</YR>
<VL>78</VL>
<PG>166-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mcleod-2001" NAME="Mcleod 2001" YEAR="2001">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mcleod RS, Geerts WH, Sniderman K, Greenwood C, Gregoire RC Taylor BM, Silverman RE, Atkinson KG, Burnstein M, Marshall JC, Burul, CJ, Anderson DR, Ross T, Wilson SR, Barton P and other invetigators of the Canadian Colorectal Surgery DVT Prophylaxis Trial.</AU>
<TI>Subcutaneous Heparin Versus Low-Molecular- Weight Heparin as Thromboprophylaxis in patients undergoung Colorectal Surgery. Results of the Canadian Colorectal DVT Prophylaxis Trial: A Randomized, Double-BlindTrial.</TI>
<SO>Annals of Surgery</SO>
<YR>2001</YR>
<VL>233</VL>
<NO>3</NO>
<PG>438-444</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Negus-1980" NAME="Negus 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Negus D, Friedgood A</AU>
<TI>Ultra-low dose intravenous heparin in the prevention of postoperative deep vein thrombosis</TI>
<SO>Lancet</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>891-894</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="523"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicolaides-1983" NAME="Nicolaides 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicolaides AN, Miles C, Hoare M, Jury P, Helmis E, Venniker R</AU>
<TI>Intermittent sequential pneumatic compression of the legs and thromboembolism-deterrent stockings in the prevention of postoperative deep venous thrombosis</TI>
<SO>Surgery</SO>
<YR>1983</YR>
<VL>94</VL>
<NO>1</NO>
<PG>21-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83224179"/>
<IDENTIFIER TYPE="OTHER" VALUE="346"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Onarheim-1986" NAME="Onarheim 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Onarheim H, Lund T, Heimdal A, Arnesjo B</AU>
<TI>A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis</TI>
<SO>Acta Chir Scand</SO>
<YR>1986</YR>
<VL>152</VL>
<PG>593-596</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87123126"/>
<IDENTIFIER TYPE="OTHER" VALUE="356"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rem-1975" NAME="Rem 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rem J, Duckert F, Fridrich R, Gruber UF</AU>
<TI>Subcutaneous small heparin doses for the prevention of thrombosis in general surgery and urology</TI>
<TO>Subcutane kleine heparindosen zur thromboseprophylaxe in der allgemeinen chirurgie und urologie</TO>
<SO>Schweiz Med Wochenschr</SO>
<YR>1975</YR>
<VL>105</VL>
<NO>26</NO>
<PG>827-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76129481"/>
<IDENTIFIER TYPE="OTHER" VALUE="384"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torngren-1978" NAME="Torngren 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Torngren S, Forsberg K</AU>
<TI>Concentrated or diluted heparin prophylaxis of postoperative deep venous thrombosis</TI>
<SO>Acta-Chir-Scand</SO>
<YR>1978</YR>
<VL>144</VL>
<PG>283-285</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CN-00202745 - CCTR. MEDLINE 79100149 EMBASE 79071859"/>
<IDENTIFIER TYPE="OTHER" VALUE="454"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valle-1988" NAME="Valle 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Valle I, Sola G, Origone A</AU>
<TI>Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep venous thrombosis</TI>
<SO>Curr-Med-Res-Opin</SO>
<YR>1988</YR>
<VL>11</VL>
<PG>80-86</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CN-00068595 - CCTR. MEDLINE 89120181"/>
<IDENTIFIER TYPE="OTHER" VALUE="468"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wille_x002d_J_x00f8_rgensen-1986" NAME="Wille-Jørgensen 1986" YEAR="1986">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wille-Jorgensen P</AU>
<TI>Lavdosis-heparin kombineret med enten dihyroergotamin eller graderede støttestrømper</TI>
<TO>Low-dosage heparin combined with either dihydroergotamine or graduated supportive stockings. Combined prevention of thrombosis in colonic surgery]</TO>
<SO>Ugeskr Laeger</SO>
<YR>1986</YR>
<VL>148</VL>
<PG>501-503</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="86181188"/>
<IDENTIFIER TYPE="OTHER" VALUE="492"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wille_x002d_J_x00f8_rgensen-1991" NAME="Wille-Jørgensen 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wille-Jorgensen P, Hauch O, Dimo B, Christensen SW, Jensen R, Hansen B</AU>
<TI>Prophylaxis of deep venous thrombosis after acute abdominal operation</TI>
<SO>Surg Gynecol Obstet</SO>
<YR>1991</YR>
<VL>172</VL>
<PG>44-48</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="493"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bounameaux-1993" NAME="Bounameaux 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Bounameaux H, Huber O, Khabiri E, Schneider PA, Didier D, Rohner A. Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin. Arch Surg. 128. 1993:326-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bounameaux H, Huber O, Khabiri E, Schneider PA, Didier D, Rohner A</AU>
<TI>Unexpectedly high rate of phlebographic deep venous thrombosis following elective general abdominal surgery among patients given prophylaxis with low-molecular-weight heparin.</TI>
<SO>Arch Surg.</SO>
<YR>1993</YR>
<VL>128</VL>
<PG>326-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Browse--1974" NAME="Browse  1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;alternate leg&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Browse NL, Jackson BT, Mayo ME, Negus</AU>
<TI>The value of mechanical methods of preventing postoperative calf vein thrombosis</TI>
<SO>Br.J.Surg</SO>
<YR>1974</YR>
<VL>61</VL>
<NO>3</NO>
<PG>219-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="529"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comerota-1986-A" NAME="Comerota 1986 A" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Comerota AJ. Review of the Multicenter Trial Committee report: a prospective, randomized study on the prophylaxis of postoperative deep venous thrombosis. Pharmacotherapy. 6. 1986:18S-22S.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comerota AJ</AU>
<TI>Review of the Multicenter Trial Committee report: a prospective, randomized study on the prophylaxis of postoperative deep venous thrombosis.</TI>
<SO>Pharmacotherapy.</SO>
<YR>1986</YR>
<VL>6</VL>
<PG>18S-22S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-1982" NAME="Ellis 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Ellis H, Scurr JH. Prophylaxis of venous thrombosis. Phlebologie. 35. 1982:135-42.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ellis H, Scurr JH</AU>
<TI>Prophylaxis of venous thrombosis.</TI>
<SO>Phlebologie</SO>
<YR>1982</YR>
<VL>35</VL>
<PG>135-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallus-1993" NAME="Gallus 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Gallus-A, Cade-J, Ockelford-P et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group. 70. 1993:562-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallus A, Cade J, Ockelford P, Hepburn S, Maas M, Magnani H, Bucknall T, Stevens J, Porteous F.</AU>
<TI>Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group.</TI>
<SO>Thromb Haemost.</SO>
<YR>1993</YR>
<VL>70</VL>
<PG>562-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar--1993" NAME="Kakkar  1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;doublepublication&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV</AU>
<TI>Multicentre randomized double-blind trial of low molecular weight heparin and standard heparin for prevention of postoperative venous thromboembolism in major abdominal surgery</TI>
<SO>British Journal Of Surgery</SO>
<YR>1993</YR>
<VL>80</VL>
<PG>S112</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CN-00128856"/>
<IDENTIFIER TYPE="OTHER" VALUE="253"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mcleod--1995" NAME="Mcleod  1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mcleod RS, Geerts WH, Sniderman K, Greenwood C, Gregoire R, Taylor B et al</AU>
<TI>Thromboprophylaxis in colorectal surgery - A randomized trial comparing low dose heparin and enoxaparin</TI>
<SO>Thrombosis and Haemostasis</SO>
<YR>1995</YR>
<VL>73</VL>
<NO>6</NO>
<PG>973, no 309</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="517"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-No-author-1984" NAME="No author 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>No authors listed</AU>
<TI>Prophylactic efficacy of low-dose dihydroergotamine and heparin in postoperative deep venous thrombosis following intra-abdominal operations</TI>
<SO>J Vasc Surg</SO>
<YR>1984</YR>
<VL>1</VL>
<PG>608-16</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85058460"/>
<IDENTIFIER TYPE="OTHER" VALUE="PubMed 6389909"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rasmussen--1988" NAME="Rasmussen  1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rasmussen A, Hansen PT, Lindholt J, Poulsen, T, Toftdahl DB, Gram J, Toftgaard C, Jespersen J</AU>
<TI>Venous thrombosis after abdominal surgery. A comparison between subcutaneous heparin and antithrombotic stockings, or both</TI>
<SO>J-Med</SO>
<YR>1988</YR>
<VL>19</VL>
<NO>3 and 4</NO>
<PG>193-201</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CN-00068984 - CCTR. MEDLINE 89035909"/>
<IDENTIFIER TYPE="OTHER" VALUE="1079"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strand-1975" NAME="Strand 1975" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strand L, Bank-Mikkelsen OK, Lindewald H</AU>
<TI>Small heparin doses as prophylaxis against deep-vein thrombosis in major surgery</TI>
<SO>Acta-Chir-Scand</SO>
<YR>1975</YR>
<VL>141</VL>
<PG>624-627</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CN-00195984 - CCTR. MEDLINE 76108173"/>
<IDENTIFIER TYPE="OTHER" VALUE="441"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torngren-1982" NAME="Torngren 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;historical controls.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torngren S, Rieger A</AU>
<TI>Prophylaxis of deep venous thrombosis in colorectal surgery</TI>
<SO>Dis Colon Rectum</SO>
<YR>1982</YR>
<VL>25</VL>
<NO>6</NO>
<PG>563-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="458"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-T_x00f6_rngren-1980" NAME="Törngren 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torngren S</AU>
<TI>Low dose heparin and compression stockings in the prevention of postoperative deep venous thrombosis</TI>
<SO>Br J Surg</SO>
<YR>1980</YR>
<VL>67</VL>
<NO>7</NO>
<PG>482-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="81022208"/>
<IDENTIFIER TYPE="OTHER" VALUE="453"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Adolf-1989" NAME="Adolf 1989" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Adolf J, Knee H, Roder JD, van de Flierdt E, Siewert JR. Thromboembolism prophylaxis with low molecular weight heparin in abdominal surgery. Dtsch Med Wochenschr. 114. 1989:48-53.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adolf J, Knee H, Roder JD, van de Flierdt E, Siewert JR</AU>
<TI>Thromboembolism prophylaxis with low molecular weight heparin in abdominal surgery</TI>
<SO>Dtsch Med Wochenschr</SO>
<YR>1989</YR>
<VL>114</VL>
<PG>48-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist--1980" NAME="Bergqvist  1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Bergqvist D, Efsing HO, Hallbook T, Lindblad B. Prevention of postoperative thromboembolic complications. A prospective comparison between dextran 70, dihydroergotamin, heparin and a sulphated polysaccharid. 146. 1980:559-68.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Efsing HO, Hallbook T, Lindblad B</AU>
<TI>Prevention of postoperative thromboembolic complications. A prospective comparison between dextran 70, dihydroergotamin, heparin and a sulphated polysaccharid. 146</TI>
<SO>Acta Chir Scand</SO>
<YR>1980</YR>
<VL>556</VL>
<PG>559-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist--1990-A" NAME="Bergqvist  1990 A" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Bergqvist D, Burmark US, Frisell J et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. Semin Thromb Hemost. 16 Suppl. 1990:19-24.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Burmark US, Frisell J, Guilbaud O, Hallbook T, Horn A et al</AU>
<TI>Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin.</TI>
<SO>Semin Thromb Hemost</SO>
<YR>1990</YR>
<VL>16 Suppl</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-1986-A" NAME="Bergqvist 1986 A" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Bergqvist D BUFJHTLBRBTSWG. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prosepctive double-blind multicentre trial on prevention of postoperative thrombosis. Br.J.Surg. 73. 1986:204-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D</AU>
<TI>Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prosepctive double-blind multicentre trial on prevention of postoperative thrombosis</TI>
<SO>Br.J.Surg.</SO>
<YR>1986</YR>
<VL>73</VL>
<PG>204-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-1986-B" NAME="Bergqvist 1986 B" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Bergqvist-D, Burmark-US, Frisell-J et al. Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications. 1986:11-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B et al</AU>
<TI>Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications</TI>
<SO>Haemostasis</SO>
<YR>1986</YR>
<VL>16 Suppl:2</VL>
<PG>11-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-1988-B" NAME="Bergqvist 1988 B" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Bergqvist D, Matzsch T, Burmark US et al. Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis [published erratum appears in Br J Surg 1988 Nov;75(11):1077]. Br J Surg. 75. 1988:888-91.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Matzsch T, Burmark US, Frisell J, Guilbaud O, Hallbook T et al</AU>
<TI>Low molecular weight heparin given the evening before surgery compared with conventional low-dose heparin in prevention of thrombosis [published erratum appears in Br J Surg 1988 Nov;75(11):1077]</TI>
<SO>Br J Surg.</SO>
<YR>1988</YR>
<VL>75</VL>
<NO>11</NO>
<PG>888-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-1990-B" NAME="Bergqvist 1990 B" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Bergqvist-D, Burmark-US, Frisell-J et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. 1990:19-24.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Burmark US, Frisell J, Guilbaud O, Hallbook T, Horn A et al</AU>
<TI>Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin</TI>
<SO>Semin Thromb Hemost</SO>
<YR>1990</YR>
<VL>16 Suppl.</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-1992" NAME="Bergqvist 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Bergqvist D, Lindgren B, Matzsch T. Glycosaminnoglycans in prophylaxis against venous thromboembolism. Adv. Exp. Med.. Biol. 313. 1992:259-74.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Lindgren B, Matzsch T</AU>
<TI>Glycosaminnoglycans in prophylaxis against venous thromboembolism</TI>
<SO>Adv Exp Med Biol</SO>
<YR>1992</YR>
<VL>313</VL>
<PG>259-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-1995" NAME="Bergqvist 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Bergqvist D, Burmark US, Flordal PA et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients. 82. 1995:496-501.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallbook T, Hedberg M et al</AU>
<TI>Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 XaI units in 2070 patients</TI>
<SO>British Journal of Surgery</SO>
<YR>1995</YR>
<VL>82</VL>
<PG>496-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergqvist-1996" NAME="Bergqvist 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Bergqvist-D, Flordal-PA, Friberg-B et al. Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial. 25. 1996:156-60.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergqvist D, Flordal PA, Friberg B, Frisell J, Hedberg M, Ljungstrom KG et al</AU>
<TI>Thromboprophylaxis with a low molecular weight heparin (tinzaparin) in emergency abdominal surgery. A double-blind multicenter trial</TI>
<SO>Vasa</SO>
<YR>1996</YR>
<VL>25</VL>
<PG>156-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boneu-1993" NAME="Boneu 1993" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Boneu B. An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. Blood Coagul Fibrinolysis. 4 Suppl 1. 1993:S21-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boneu B</AU>
<TI>An international multicentre study: Clivarin in the prevention of venous thromboembolism in patients undergoing general surgery. Report of the International Clivarin Assessment Group. .</TI>
<SO>Blood Coagul Fibrinolysis</SO>
<YR>1993</YR>
<VL>4 Suppl 1</VL>
<PG>S21-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Borow-1983" NAME="Borow 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borow M, Goldson HJ</AU>
<TI>Prevention of Postoperative Deep Venous Thrombosis and Pulmonary Emboli with Combined Modalities</TI>
<SO>Am Surg</SO>
<YR>1983</YR>
<VL>49</VL>
<PG>599-605</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Breddin-1983" NAME="Breddin 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Breddin K, Haring R, Koppenhagen K. [Prevention of postoperative thrombotic complications with heparin and dihydroergotamine. A randomized double-blind study]. Dtsch Med Wochenschr. 108. 1983:98-102.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breddin K, Haring R, Koppenhagen K</AU>
<TI>Prevention of postoperative thrombotic complications with heparin and dihydroergotamine. A randomized double-blind study.</TI>
<SO>Dtsch Med Wochenschr.</SO>
<YR>1983</YR>
<VL>108</VL>
<PG>98-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buttermann-1977" NAME="Buttermann 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Buttermann G, Theisinger W, Weidenbach A, Hartung R, Welzel D, Pabst HW. [Quantitative assessment of drug-induced prophylaxis of postoperative thromboembolism. Comparison of frequencies of deep vein thrombosis and pulmonary embolism using acetylsalicylic-acid, dextran, dihydroergotamine, low-dose heparin and the fixed combination of heparin and dihydroergotamine (author's transl)]. &lt;br&gt; Med Klin. 72. 1977:1624-38.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buttermann G, Theisinger W, Weidenbach A, Hartung R, Welzel D, Pabst HW</AU>
<TI>[Quantitative assessment of drug-induced prophylaxis of postoperative thromboembolism. Comparison of frequencies of deep vein thrombosis and pulmonary embolism using acetylsalicylic-acid, dextran, dihydroergotamine, low-dose heparin and the fixed combination of heparin and dihydroergotamine (author's transl)].</TI>
<SO>Med Klin.</SO>
<YR>1977</YR>
<VL>72</VL>
<PG>1624-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cade-1987" NAME="Cade 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Cade JF, Wood M, Magnani HN, Westlake GW. Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis. Thromb Res. 45. 1987:497-503.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cade JF, Wood M, Magnani HN, Westlake GW</AU>
<TI>Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis.</TI>
<SO>Thromb Res</SO>
<YR>1987</YR>
<VL>45</VL>
<PG>497-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caen-1988" NAME="Caen 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial. Thromb Haemost. 59. 1988:216-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caen JP</AU>
<TI>A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. A French multicenter trial.</TI>
<SO>Thromb Haemost.</SO>
<YR>1988</YR>
<VL>59</VL>
<PG>216-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Comerota--1986-B" NAME="Comerota  1986 B" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Comerota AJ, White JV. The use of dihydroergotamine and heparin in the prophylaxis of deep venous thrombosis. Chest. 89. 1986:389S-95S.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Comerota AJ, White JV</AU>
<TI>The use of dihydroergotamine and heparin in the prophylaxis of deep venous thrombosis.</TI>
<SO>Chest</SO>
<YR>1986</YR>
<VL>89</VL>
<PG>389S-95S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Creperio-1990" NAME="Creperio 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Creperio G, Marabini M, Ciocia G, Bergonzi M, Fincato M. [Evaluation of the effectiveness and safety of Fragmin (Kabi 2165) versus calcium heparin in the prevention of deep venous thrombosis in general surgery]. Minerva Chir. 45. 1990:1101-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Creperio G, Marabini M, Ciocia G, Bergonzi M, Fincato M</AU>
<TI>[Evaluation of the effectiveness and safety of Fragmin (Kabi 2165) versus calcium heparin in the prevention of deep venous thrombosis in general surgery].</TI>
<SO>Minerva Chir</SO>
<YR>1990</YR>
<VL>45</VL>
<PG>1101-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EFS-1988" NAME="EFS 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;The European Fraxiparin Study (EFS) Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group. Br J Surg. 75. 1988:1058-63.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The European Fraxiparin Study (EFS) Group</AU>
<TI>Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. The European Fraxiparin Study (EFS) Group</TI>
<SO>Br J Surg.</SO>
<YR>1988</YR>
<VL>75</VL>
<PG>1058-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Encke-1988" NAME="Encke 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Encke A. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg. 75. 1988:1058-63.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Encke A</AU>
<TI>Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery.</TI>
<SO>Br J Surg</SO>
<YR>1988</YR>
<VL>75</VL>
<PG>1058-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Enoxacan-1997" NAME="Enoxacan 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Enoxacan Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 84. 1997:1099-103.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Enoxacan Study Group</AU>
<TI>Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group.</TI>
<SO>Br J Surg</SO>
<YR>1997</YR>
<VL>84</VL>
<PG>1099-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garcea-1992" NAME="Garcea 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Garcea D, Martuzzi F, Santelmo N et al. Post-surgical deep vein thrombosis prevention: evaluation of the risk/benefit ratio of fractionated and unfractionated heparin. Curr Med Res Opin. 12. 1992:572-83.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garcea D, Martuzzi F, Santelmo N, Savoia M, Casertano MG, Furno A et al</AU>
<TI>Post-surgical deep vein thrombosis prevention: evaluation of the risk/benefit ratio of fractionated and unfractionated heparin</TI>
<SO>Curr Med Res Opin.</SO>
<YR>1992</YR>
<VL>12</VL>
<PG>572-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gazzaniga-1993" NAME="Gazzaniga 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Gazzaniga GM, Angelini G, Pastorino G, Santoro E, Lucchini M, Dal Pra ML. Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study. The Italian Study Group. Int Surg. 78. 1993:271-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gazzaniga GM, Angelini G, Pastorino G, Santoro E, Lucchini M, Dal Pra ML</AU>
<TI>Enoxaparin in the prevention of deep venous thrombosis after major surgery: multicentric study. The Italian Study Group</TI>
<SO>Int Surg</SO>
<YR>1993</YR>
<VL>78</VL>
<PG>271-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gruber-1977" NAME="Gruber 1977" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Gruber-UF, Duckert-F, Fridrich-R, Torhorst-J, Rem-J. Prevention of postoperative thromboembolism by dextran 40, low doses of heparin, or xantinol nicotinate. 1. 1977:207-10.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gruber UF, Duckert F, Fridrich R, Torhorst J, Rem J</AU>
<TI>Prevention of postoperative thromboembolism by dextran 40, low doses of heparin, or xantinol nicotinate</TI>
<SO>Lancet</SO>
<YR>1977</YR>
<VL>1</VL>
<PG>207-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartl-1990" NAME="Hartl 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Hartl P, Brucke P, Dienstl E, Vinazzer H. Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res. 57. 1990:577-84.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartl P, Brucke P, Dienstl E, Vinazzer H</AU>
<TI>Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragming</TI>
<SO>Thromb Res</SO>
<YR>1990</YR>
<VL>57</VL>
<PG>577-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heather-1982" NAME="Heather 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Heather BP, Greenhalgh RM. Prophylaxis of early post operative deep venous thrombosis by monitored heparin infusion. Phlebologie. 35. 1982:173-85.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heather BP, Greenhalgh RM</AU>
<TI>Prophylaxis of early post operative deep venous thrombosis by monitored heparin infusion</TI>
<SO>Phlebologie</SO>
<YR>1982</YR>
<VL>35</VL>
<PG>173-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar-1972" NAME="Kakkar 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Kakkar VV, Corrigan T, Spindler J., Fossard DP, Flute PT, Crellin RQ. Efficacy of low doses of heparin in prevention of deepvein thrombosis after major surgery. ii. 1972:101-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Corrigan T, Spindler J, , Fossard DP, Flute PT, Crellin RQ</AU>
<TI>Efficacy of low doses of heparin in prevention of deepvein thrombosis after major surgery</TI>
<SO>Lancet</SO>
<YR>1972</YR>
<VL>2</VL>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar-1985" NAME="Kakkar 1985" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Kakkar-VV, Murray-WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. 72. 1985:786-91.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Murray WJ</AU>
<TI>Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study</TI>
<SO>Br J Surg</SO>
<YR>1985</YR>
<VL>72</VL>
<PG>786-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar-1986" NAME="Kakkar 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Kakkar VV, Kakkar S, Sanderson RM, Peers CE. Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism. Haemostasis. 16 Suppl 2. 1986:19-24.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Kakkar S, Sanderson RM, Peers CE</AU>
<TI>Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism.</TI>
<SO>Haemostasis</SO>
<YR>1986</YR>
<VL>16 Suppl 2</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar-1993" NAME="Kakkar 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Kakkar-VV, Cohen-AT, Edmonson-RA et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group [see comments]. 341. 1993:259-65.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das S et al</AU>
<TI>Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group [see comments]</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>341</VL>
<PG>259-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kakkar-1997" NAME="Kakkar 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Kakkar VV, Boeckl O, Boneu B et al. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg. 21. 1997:2-8; discussion 8-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kakkar VV, Boeckl O, Boneu B, Bordenave L, Brehm OA, Brucke P et al</AU>
<TI>Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial</TI>
<SO>World J Surg</SO>
<YR>1997</YR>
<VL>21</VL>
<PG>2-8; discussion 8-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koller-1986" NAME="Koller 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Koller M, Schoch U, Buchmann P, Largiader F, von Felten A, Frick PG. Thrombosis prophylaxis in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7,500 and 2,500 anti-Xa IU/day). Haemostasis. 16 Suppl 2. 1986:69-70.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koller M, Schoch U, Buchmann P, Largiader F, von Felten A, Frick PG</AU>
<TI>Thrombosis prophylaxis in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7,500 and 2,500 anti-Xa IU/day).</TI>
<SO>Haemostasis.</SO>
<YR>1986</YR>
<VL>16 Suppl 2</VL>
<PG>69-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosir-1998" NAME="Kosir 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Kosir MA, Schmittinger L, Barno Winarski L et al. Prospective double-arm study of fibrinolysis in surgical patients. J Surg Res. 74. 1998:96-101.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosir MA, Schmittinger L, Barno Winarski L, Duddella P, Pone M, Perales A. et al</AU>
<TI>Prospective double-arm study of fibrinolysis in surgical patients</TI>
<SO>J Surg Res</SO>
<YR>1998</YR>
<VL>74</VL>
<PG>96-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lahnborg-1975" NAME="Lahnborg 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Lahnborg-G, Bergstrom-K. Clinical and haemostatic parameters related to thromboembolism and low-dose heparin prophylaxis in major surgery. 141. 1975:590-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lahnborg G, Bergstrom K</AU>
<TI>Clinical and haemostatic parameters related to thromboembolism and low-dose heparin prophylaxis in major surgery</TI>
<SO>Acta Chir Scand</SO>
<YR>1975</YR>
<VL>141</VL>
<NO>7</NO>
<PG>590-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lareng-1978" NAME="Lareng 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Lareng L, Vaysse C, Plante J, et al. Prevention of postoperative thromboembolic disease in general surgery. A randomized trial of two therapeutic procedures evaluated by the method of I labelled fibrinogen. 35. 1978:1185-93.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lareng L, Vaysse C, Plante J, Boneu B, Gouzi M</AU>
<TI>Prevention of postoperative thromboembolic disease in general surgery. A randomized trial of two therapeutic procedures evaluated by the method of I labelled fibrinogen</TI>
<SO>Anaesth Analg (Paris)</SO>
<YR>1978</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1185-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leypold-1984" NAME="Leypold 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Leypold J, Privara M, Stepankova S. [Prevention of postoperative thromboembolic accidents using small doses of heparin]. 63. 1984:611-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leypold J, Privara M, Stepankova S</AU>
<TI>[Prevention of postoperative thromboembolic accidents using small doses of heparin].</TI>
<SO>Rozhl Chir</SO>
<YR>1984</YR>
<VL>63</VL>
<NO>8-9</NO>
<PG>611-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liezorovicz-1991" NAME="Liezorovicz 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Liezorovicz A, Picolet H, Peyrieux JC, Boissel JP. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group. Br J Surg. 78. 1991:412-16.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liezorovicz A, Picolet H, Peyrieux JC, Boissel JP</AU>
<TI>Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double blind study comparing two doses of Logiparin and standard heparin. H.B.P.M. Research Group.</TI>
<SO>Br J Surg</SO>
<YR>1991</YR>
<VL>78</VL>
<PG>412-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Limmer-1994" NAME="Limmer 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Limmer J, Ellbruck D, Muller H et al. Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis. Clin Investig. 72. 1994:913-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Limmer J, Ellbruck D, Muller H et al</AU>
<TI>Prospective randomized clinical study in general surgery comparing a new low molecular weight heparin with unfractionated heparin in the prevention of thrombosis.</TI>
<SO>Clin Investig.</SO>
<YR>1994</YR>
<VL>72</VL>
<PG>913-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marassi-1993" NAME="Marassi 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Marassi A, Balzano G, Mari G et al. Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216). Int Surg. 78. 1993:166-70.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marassi A, Balzano G, Mari G et al</AU>
<TI>Prevention of postoperative deep vein thrombosis in cancer patients. A randomized trial with low molecular weight heparin (CY 216).</TI>
<SO>Int Surg.</SO>
<YR>1993</YR>
<VL>78</VL>
<PG>166-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McLeod-1996" NAME="McLeod 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;McLeod RS. The risk of thromboembolism in patients undergoing colorectal surgery. 52 Suppl 7. 1996:38-41.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McLeod RS</AU>
<TI>The risk of thromboembolism in patients undergoing colorectal surgery.</TI>
<SO>Drugs</SO>
<YR>1996</YR>
<VL>52 Suppl 7</VL>
<PG>38-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moreno-1996" NAME="Moreno 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Moreno Gonzalez E, Fontcuberta J, de la Llama F. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. EMRO1 (Grupo Fstudio Multicintrico RO-11). Hepatogastroenterology. 43. 1996:744-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moreno Gonzalez E, Fontcuberta J, de la Llama F</AU>
<TI>Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. EMRO1 (Grupo Fstudio Multicintrico RO-11).</TI>
<SO>Hepatogastroenterology.</SO>
<YR>1996</YR>
<VL>43</VL>
<PG>744-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Moser-1976" NAME="Moser 1976" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moser G, Froideveaux A</AU>
<TI>Prophylaxis of Post-operative deep venous thrombosis using small sub-cutaneous heparin doses, associated or not with compressive stockings: comparative study and results</TI>
<TO>Prophylaxxie des thromboses veineuses profondes postopératoires par des petites doses d´Heparin souscutanes associées ou non au port de bas compressif: étude comparative et résultats</TO>
<SO>Schweiz Rundschau Med</SO>
<YR>1976</YR>
<VL>65</VL>
<PG>1015-20.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-M_x00fc_he-1984" NAME="Mühe 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;M&amp;#252;he E. Intermittent sequential high-pressure compression of the leg. A new method of preventing deep vein thrombosis. 147. 1984:781-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mühe E</AU>
<TI>Intermittent sequential high-pressure compression of the leg. A new method of preventing deep vein thrombosis.</TI>
<SO>Am J Surg</SO>
<YR>1984</YR>
<VL>147</VL>
<NO>6</NO>
<PG>781-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Negus-1982" NAME="Negus 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Negus D, Friedgood A. Ultra-low dose intravenous heparin in the prevention of postoperative deep vein thrombosis. 35. uk: 1982:247-58.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Negus D, Friedgood A</AU>
<TI>Ultra-low dose intravenous heparin in the prevention of postoperative deep vein thrombosis.</TI>
<SO>Phlebologie</SO>
<YR>1982</YR>
<VL>35</VL>
<PG>247-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicolaides-1972" NAME="Nicolaides 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;Nicolaides AN DPDNLJDSJCW. Small doses of subcutaneous hepatin preventing deep.vein thrombosis in major surgery. Br.J.Surg. 59. 1972.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nicolaides AN, Dupont P, Douglas N, Lewis JD, Desai S, Jamieson CW</AU>
<TI>Small doses of subcutaneous hepatin preventing deep.vein thrombosis in major surgery</TI>
<SO>Br.J.Surg.</SO>
<YR>1972</YR>
<VL>59</VL>
<PG>911</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nurmohamed-1995" NAME="Nurmohamed 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Nurmohamed MT, Verhaeghe R, Haas S et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg. 169. 1995:567-71.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Rij AM et al</AU>
<TI>A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery</TI>
<SO>Am J Surg</SO>
<YR>1995</YR>
<VL>169</VL>
<PG>567-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ockelford-1989" NAME="Ockelford 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost. 62. 1989:1046-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ockelford PA, Patterson J, Johns AS</AU>
<TI>A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin).</TI>
<SO>Thromb Haemost.</SO>
<YR>1989</YR>
<VL>62</VL>
<PG>1046-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pezzuoli-1989" NAME="Pezzuoli 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Pezzuoli G, Neri Serneri GG, Settembrini P et al. Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group. Int Surg. 74. 1989:205-10.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pezzuoli G, Neri Serneri GG, Settembrini P, Coggi G, Olivari N, Buzzetti G et al</AU>
<TI>Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP). STEP-Study Group</TI>
<SO>Int Surg</SO>
<YR>1989</YR>
<VL>74</VL>
<PG>205-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pezzuoli-1990" NAME="Pezzuoli 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Pezzuoli-G, Neri-Serneri-GG, Settembrini-PG et al. Effectiveness and safety of the low-molecular-weight heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. A multicentre, double-blind, randomized, controlled clinical trial versus placebo (STEP). STEP Study Group. 1990:193-204.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Codemo R, Galli G, Roveri S. Pezzuoli G, Neri-Serneri GG, Settembrini PG, Coggi G, OlivariN, Negri G, Codemo R, Galli G, Roveri S.</AU>
<TI>Effectiveness and safety of the low-molecular-weight heparin CY 216 in the prevention of fatal pulmonary embolism and thromboembolic death in general surgery. A multicentre, double-blind, randomized, controlled clinical trial versus placebo (STEP). STEP Study Group</TI>
<SO>Haemostatis</SO>
<YR>1990</YR>
<VL>20 Suppl. 1</VL>
<PG>193-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plante-1979" NAME="Plante 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Plante J, Boneu B, Vaysse C, Barret A, Gouzi M, Bierme R. Dipyridamole-aspirin versus low doses of heparin in the prophylaxis of deep venous thrombosis in abdominal surgery. Thromb Res. 14. 1979:399-403.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plante J, Boneu B, Vaysse C, Barret A, Gouzi M, Bierme R</AU>
<TI>Dipyridamole-aspirin versus low doses of heparin in the prophylaxis of deep venous thrombosis in abdominal surgery.</TI>
<SO>Thromb Res. 14</SO>
<YR>1979</YR>
<VL>14</VL>
<PG>399-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roberts-1974" NAME="Roberts 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Roberts VC CL. Prevention of postoperative deep vein thrombosis in patients with malignant disease. British Medical Journal. 1. 1974:358-60.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roberts VC CL</AU>
<TI>Prevention of postoperative deep vein thrombosis in patients with malignant disease.</TI>
<SO>British Medical Journal</SO>
<YR>1974</YR>
<VL>1</VL>
<PG>358-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodiger-1991" NAME="Rodiger 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Rodiger H, Nowak W, Kneist W. [Quality requirements in clinical studies in surgery exemplified by prevention of thromboembolism]. Zentralbl Chir. 116. 1991:757-60.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodiger H, Nowak W, Kneist W</AU>
<TI>[Quality requirements in clinical studies in surgery exemplified by prevention of thromboembolism].</TI>
<SO>Zentralbl Chir.</SO>
<YR>1991</YR>
<VL>116</VL>
<PG>757-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenberg-1975" NAME="Rosenberg 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Rosenberg IL EMPA. Prophylaxis of postoperative leg vein thrombosis by low dose subcutaneous heparin or perioperative calf muscle stimulation: A controlled clinical trial. BMJ. 1. 1975:649-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg IL EMPA</AU>
<TI>Prophylaxis of postoperative leg vein thrombosis by low dose subcutaneous heparin or perioperative calf muscle stimulation: A controlled clinical trial.</TI>
<SO>BMJ</SO>
<YR>1975</YR>
<VL>1</VL>
<PG>649-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samama-1988" NAME="Samama 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Samama M, Bernard P, Bonnardot JP, Combe Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg. 75. 1988:128-31.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E</AU>
<TI>Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis</TI>
<SO>Br J Surg</SO>
<YR>1988</YR>
<VL>75</VL>
<PG>128-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samama-1989" NAME="Samama 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Samama M C-TS. Prevention of thromboembolic disease in general surgery with enoxaparin. Br.J.Clin.Pract.suppl. 65. 1989:9-17.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samama M, Combe-Tamzali S</AU>
<TI>Prevention of thromboembolic disease in general surgery with enoxaparin</TI>
<SO>Br.J.Clin.Pract.suppl</SO>
<YR>1989</YR>
<VL>65</VL>
<PG>9-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samama-1990" NAME="Samama 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Samama M, Combe S. Prevention of thromboembolic disease in general surgery with enoxaparin (Clexane). Acta Chir Scand Suppl. 556. 1990:91-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samama M, Combe S</AU>
<TI>Prevention of thromboembolic disease in general surgery with enoxaparin (Clexane)</TI>
<SO>Acta Chir Scand Suppl</SO>
<YR>1990</YR>
<VL>556</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samama-1994" NAME="Samama 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Samama-MM. Prevention of postoperative thromboembolism in general surgery with enoxaparin. 1994. 1994:31-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samama MM</AU>
<TI>Prevention of postoperative thromboembolism in general surgery with enoxaparin</TI>
<SO>Ann Cardiol Angeiol (Paris).</SO>
<YR>1994</YR>
<VL>43</VL>
<PG>31-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitz-1984" NAME="Schmitz 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Schmitz Huebner U, Bunte H, Freise G et al. Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis. Klin Wochenschr. 62. 1984:349-53.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz Huebner U, Bunte H, Freise G, Reers B, Ruschemeyer C, Scherer R et al</AU>
<TI>Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis</TI>
<SO>Klin Wochenschr</SO>
<YR>1984</YR>
<VL>62</VL>
<PG>349-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Torngren-1984" NAME="Torngren 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Torngren S, Kettunen K, Lahtinen J et al. A randomized study of a semisynthetic heparin analogue and heparin in prophylaxis of deep vein thrombosis. Br J Surg. 71. 1984:817-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torngren S, Kettunen K, Lahtinen J, Koppenhagen K, Brucke P, Hartl P et al</AU>
<TI>A randomized study of a semisynthetic heparin analogue and heparin in prophylaxis of deep vein thrombosis</TI>
<SO>Br J Surg</SO>
<YR>1984</YR>
<VL>71</VL>
<PG>817-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verardi-1988" NAME="Verardi 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Verardi S, Casciani CU, Nicora E et al. A multicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis. Int Angiol. 7. 1988:19-24.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verardi S, Casciani CU, Nicora E et al</AU>
<TI>A multicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis.</TI>
<SO>Int Angiol</SO>
<YR>1988</YR>
<VL>7</VL>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zawilska-1990" NAME="Zawilska 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Zawilska-K, Tokarz-A, Misiak-A et al. Nebulized heparin and anabolic steroid in the prevention of postoperative deep vein thrombosis following elective abdominal surgery. 117. 1990:699-707.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meissner J, Karon J, Lewandowski K, Lopaciuk S, et al. Zawilska K, Tokarz A, Misiak A, Psuja P, Wislawski S, Szymczak P, Meissner J, Karon J, Lewandowski K, Lopaciuk S, et al.</AU>
<TI>Nebulized heparin and anabolic steroid in the prevention of postoperative deep vein thrombosis following elective abdominal surgery</TI>
<SO>Folia Haematol Int Mag Klin Morphol Blutforsch</SO>
<YR>1990</YR>
<VL>117</VL>
<PG>699-707</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Amarigiri-2000" NAME="Amarigiri 2000" TYPE="COCHRANE_REVIEW">
<AU>Amagiri SV, Lees TA</AU>
<TI>Elastic compression stockings for the prevention of deep vein theombosis (Cochrane Review).</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Andersen-1991" NAME="Andersen 1991" TYPE="JOURNAL_ARTICLE">
<AU>Andersen M, Wille-Jørgensen P. Late complications of asymptomatic deep venous thrombosis. Eur J Surg 1991;157:527-530. Andersen M, Wille-Jørgensen P</AU>
<TI>Late complications of asymptomatic deep venous thrombosis Late complications of asymptomatic deep venous thrombosis</TI>
<SO>Eur J Surg Eur J Surg 1991;157:527-530.</SO>
<YR>1991</YR>
<VL>157 157:527-530.</VL>
<PG>527-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clagett--1995" NAME="Clagett  1995" NOTES="&lt;p&gt;Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995.108,312S-34S. Review. Unknown.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Clagett GP, Anderson FA, Heit J, Levine MN, Wheeler HB</AU>
<TI>Prevention of venous thromboembolism. Chest 1995</TI>
<SO>Chest</SO>
<YR>1995</YR>
<VL>108</VL>
<PG>312s-33s</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1460"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clagett-1988" NAME="Clagett 1988" NOTES="&lt;p&gt;Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Ann Surg 1988;208:227-40. Review. crossref&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Clagett GP, Reisch JS</AU>
<TI>Prevention of venous thromboembolism in general surgical patients</TI>
<SO>Ann Surg</SO>
<YR>1988</YR>
<VL>208</VL>
<PG>227-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="88293064"/>
<IDENTIFIER TYPE="OTHER" VALUE="1292"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Collaborative-1994" NAME="Collaborative 1994" TYPE="JOURNAL_ARTICLE">
<AU>Collaborative overview</AU>
<TI>Collaborative overview of randomised trials of antoplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>235-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Collins-et-al-1988" NAME="Collins et al 1988" NOTES="&lt;p&gt;Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction of fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988;318:1162-73. crossref&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Scrimgeour A, Yusuf S, Peto R</AU>
<TI>Reduction of fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin</TI>
<SO>N Engl J Med</SO>
<YR>1988</YR>
<VL>318</VL>
<PG>1162-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="CN-00072000 - CCTR. MEDLINE 88202030"/>
<IDENTIFIER TYPE="OTHER" VALUE="1078"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dauzat-1997" NAME="Dauzat 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dauzat M, Laroche JP, Deklunder G, Ayoub, J, Quére I, Lopez FM, Janbon C</AU>
<TI>Diagnosis of acute lower limb deep venous thrombosis with ultrasound: trends ans controversies</TI>
<SO>J Clin Ultrasound</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>7</NO>
<PG>343-58</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97426095"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haas-1999" NAME="Haas 1999" TYPE="JOURNAL_ARTICLE">
<AU>Haas SK, Wolf H, Encke A, Fareed J,</AU>
<TI>Prevention of fatal pulmonary embolism by low molecular weight heparin - a double blind comparison of certoparin and unfractionated heparin</TI>
<SO>Thromb Haemostas</SO>
<YR>August 1999</YR>
<VL>Supplement</VL>
<PG>491</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00f8_rgensen--1993" NAME="Jørgensen  1993" NOTES="&lt;p&gt;Jorgensen LN, Wille-Jorgensen P, Hauch O. Prophylaxis of postoperative throm boembolism with low molecular weight heparins. Br J Surg 1993;80:689-704. Crossref&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Jorgensen LN, Wille-Jorgensen P, Hauch O</AU>
<TI>Prophylaxis of postoperative throm boembolism with low molecular weight heparins</TI>
<SO>Br J Surg</SO>
<YR>1993</YR>
<VL>80</VL>
<PG>689-704</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="93321028"/>
<IDENTIFIER TYPE="OTHER" VALUE="1337"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kjaergaard-1985" NAME="Kjaergaard 1985" NOTES="&lt;p&gt;Bacground that colorectal patients are at high risk. Er tilf&amp;#248;jet i teksten.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergaard J, Esbensen K, Wille Jorgensen P, Jorgensen T, Thorup J, Berning H, Wold S.</AU>
<TI>A multivariate pattern recognition study of risk-factors indicating postoperative thromboembolism despite low-dose heparin in major abdominal surgery.</TI>
<SO>Thromb Haemost</SO>
<YR>1985</YR>
<VL>54</VL>
<NO>2</NO>
<PG>409-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="86097628"/>
<IDENTIFIER TYPE="OTHER" VALUE="1365"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Leizorovicz--1997" NAME="Leizorovicz  1997" NOTES="&lt;p&gt;Leizorovicz A, Haugh MC. Low Molecular weight heparinin prevention of perioperative thrombosis (Protocol). In: Fowkes FGR, Janzon L, Kleijnen J, leng CG (eds.) Pripheral Vascular Diseases Module on The Cochrane Database of Systematic Reviews, (updated August 1997). Available in The Cochrane Library (database on CDROM). The Cochrane Collaboration; Issue 4. Oxford: Update Software; 1997. Updated Quarterly. Not in database&lt;/p&gt;" TYPE="COCHRANE_REVIEW">
<AU>Leizorovicz A, Haugh MC</AU>
<TI>Low Molecular weight heparinin prevention of perioperative thrombosis. In: Fowkes FGR, Janzon L, Kleijnen J, leng CG (eds.) Pripheral Vascular Diseases Module on The Cochrane Database of Systematic Reviews, (updated August 1997). Available in The Cochrane Library (database on CDROM). The Cochrane Collaboration; Issue 4. Oxford: Update Software; 1997</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leizorovicz-1992" NAME="Leizorovicz 1992" NOTES="&lt;p&gt;Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight hepaprin in prevention of perioperative thrombosis. Brit Med J 1992;305:913-20. Metaanalyse.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP</AU>
<TI>Low molecular weight hepaprin in prevention of perioperative thrombosis</TI>
<SO>Brit Med J</SO>
<YR>1992</YR>
<VL>305</VL>
<PG>913-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="93091577"/>
<IDENTIFIER TYPE="OTHER" VALUE="302"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mantoni-1997" NAME="Mantoni 1997" TYPE="JOURNAL_ARTICLE">
<AU>Mantoni M, Strandberg C, Neergaard K, Sloth C, Jørgensen PS, Thamsen H, Tørholm C, Paaske BP, Rasmussen SW, Christensen SW, Wille-Jørgensen P</AU>
<TI>Triplex US in the diagnosis of asymptomatic deep venous thrombosis</TI>
<SO>Acta Radiol</SO>
<YR>1997</YR>
<VL>38</VL>
<NO>2</NO>
<PG>327-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97247030"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nurmohammed-1992" NAME="Nurmohammed 1992" NOTES="&lt;p&gt;Nurmohamed MT, Rosendaal FR, Buller HR et al. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-56. Unknown reason.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Nurmohamed MT, Rosendaal FR, Buller HR et al</AU>
<TI>Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>152-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92326472"/>
<IDENTIFIER TYPE="OTHER" VALUE="1418"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Siragusa-1997" NAME="Siragusa 1997" TYPE="JOURNAL_ARTICLE">
<AU>Siragusa S, Beltrametti C, Barone M, Piovella F</AU>
<TI>Clinical course and incidence of post-thrombophlebitic syndrome after profound asymptomatic deep vein thrombosis.</TI>
<SO>Minerva Cardioangiol</SO>
<YR>1997</YR>
<VL>45</VL>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wille_x002d_Jorgensen-1991" NAME="Wille-Jorgensen 1991" NOTES="&lt;p&gt;Wille-Jorgensen, P. Prophylaxis of postoperative thromboembolism. Danish Medical Bulletin 1991;38:203-28. Discussion.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wille-Jørgensen, P</AU>
<TI>Prophylaxis of postoperative thromboembolism</TI>
<SO>Danish Medical Bulletin</SO>
<YR>1991</YR>
<VL>38</VL>
<PG>203-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wille_x002d_J_x00f8_rgensen-1988" NAME="Wille-Jørgensen 1988" NOTES="&lt;p&gt;Wille-Jorgensen P, Kjaergaard J, Jorgensen T, Korsgaard Larsen T. Failure in prophylactic management of thromboembolic disease in colorectal surgery. Dis Colon Rectum 1988;31:384-6. Discussion.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wille-Jørgensen P, Kjaergaard J, Jørgensen T, Korsgaard Larsen T</AU>
<TI>Failure in prophylactic management of thromboembolic disease in colorectal surgery</TI>
<SO>Dis Colon Rectum</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>384-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988211380"/>
<IDENTIFIER TYPE="OTHER" VALUE="1000"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wille_x002d_J_x00f8_rgensen-1990" NAME="Wille-Jørgensen 1990" NOTES="&lt;p&gt;Wille-Jorgensen P, Ott P. Predicting failure of low.dose prophylactic heparin in general surgical patients. Surg Gynecol Obstet 1990;171:126-30. Unknown reason.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wille-Jorgensen P, Ott P</AU>
<TI>Predicting failure of low.dose prophylactic heparin in general surgical patients</TI>
<SO>Surg Gynecol Obstet</SO>
<YR>1990</YR>
<VL>171</VL>
<PG>126-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1012"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wille_x002d_J_x00f8_rgensen-1992" NAME="Wille-Jørgensen 1992" NOTES="&lt;p&gt;Wille-J&amp;#248;rgensen P, J&amp;#248;rgensen LN, Hauch O, Borris LC, Lassen MR, Nehen AM, Kj&amp;#230;r L, Jensen R. Potential influence of observer variation on thromboprophylactic studies. H&amp;#230;mostasis 1992;22:211-5. Discussion.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wille-Jørgensen P, Jørgensen LN, Hauch O, Borris LC, Lassen MR, Nehen AM, Kjær L, Jensen R</AU>
<TI>Potential influence of observer variation on thromboprophylactic studies</TI>
<SO>Hæmostasis</SO>
<YR>1992</YR>
<VL>22</VL>
<PG>211-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1482"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Butson-1981">
<CHAR_METHODS>
<P>RCT. Sealed envelopes. Not blinded. (Controlgroup = no treatment). No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective general surgery patients. 119 randomized. Non excluded. Leaving 119 patients in per protocol analysis as well as in intention to treat analysis. Subgroup of 24 colorectal patients were distributed with respectively 63 % and 37 % in the two treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intermittent compression: Intermittent compression peroperatively and untill ambulant. Most of the patients 24 to 48 hours postoperatively.<BR/>Control: No treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT<BR/>Bleeding events: Not described.<BR/>Diagnosis: radiofibrinogen uptake test every day up to 14 days postoperatively or untill discharge. If positive test then confirmed with venography.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Both intention to treat- and per protocol analysis.<BR/>Unbalanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Covey-1975">
<CHAR_METHODS>
<P>RCT. Coded vials. Patient-, surgeon- and outcome-assessor blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective general surgery patients. 105 randomized. Non excluded. Leaving 105 patients in per protocol analysis as well as in intention to treat analysis. Subgroup of 20 colorectal patients were distributed with respectively 45% and 55% in the two treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH: 5000 U unfractionated heparin preoperatively and x2 postoperatively for 8 days or until discharge.<BR/>Control group: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT<BR/>Bleeding events: Not described.<BR/>Diagnosis: radiofibrinogen uptake test, until 8 th day.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No missing patients. <BR/>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Fricker-1988">
<CHAR_METHODS>
<P>RCT. Unclear randomizing procedure. Not blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective cancer general surgery. 80 randomized patients. Non excluded. Leaving 80 patients in per protocol analysis as well as in intention to treat analysis. Subgroup of 6 colorectal patients were distributed with respectively 33% and 67% in the two treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH: 5000 IU unfractionated heparin preoperatively and x3 postoperatively for ten days.<BR/>LMWH: 2500 anti-Xa units (lowdose) preoperatively and 5000 anti-Xa units (mediumdose) x1 for ten days postoperatively.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: PE<BR/>Bleeding events: Not specified in colorectal patients<BR/>Diagnosis: Radiofibrinogen uptake test. Positiv test confirmed by phlebography. PE: Clinically, confirmed by scintigraphy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Both intention to treat- and per protocol analysis.<BR/>Unbalanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Gallus-1976">
<CHAR_METHODS>
<P>RCT. Sealed envelopes. Surgeon blinded. Not patient nor outcome-assessor blinded. (Controlgroup = no treatment).<BR/>No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective general surgery patients. 820 randomized patients. Non excluded. Leaving 820 patients in per protocol analysis as well as in intention to treat analysis. Subgroup of 90 colorectal patients were distributed with respectively 49 % and 51 % in the two treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH: 5000 units of unfractionated heparin preoperatively and x3 postoperatively for seven days .<BR/>Control: No treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT<BR/>Bleeding events: Not specified in colorectal patients.<BR/>Diagnosis: radiofibrinogen uptake test, 1 to 7 th day.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Intention to treat analysis.<BR/>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ho-1999">
<CHAR_METHODS>
<P>RCT. Sealed envelopes. Surgeon blinded. Not patient nor outcome-assessor blinded. (Controlgroup = no treatment)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective surgical colorectal patients. 320 randomized patients. 17 excluded in LMWH group. Leaving 303 patients in per protocol-analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LWMH: Enoxaparin 20 mg pre-<BR/>operatively and 40 mgx1 postoperatively at least 4 days or until ambulant. <BR/>Control: No treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic:DVT, PE, Fatal PE, overall mortality.<BR/>Bleeding: Intraoperativly bloodlosses, drainage output, number of bloodtransfusions and postoperatively related complications. <BR/>Diagnosis: Clinical every day and doppler ultrasound on 3 th and 5 th post- operative day</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>17 patients missing. No intention to treat analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Joffe-1976">
<CHAR_METHODS>
<P>RCT. Computer generated list. Not blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective general surgery patients. 220 randomized patients. 17 excluded. Leaving 203 patients in per protocol analysis. Subgroup of 17 colorectal patients were distributed with respectively 47%, 18 % and 35% in the three treatment arms. Treatment arm with pentosan excluded from this analysis. Leaving 14 colorectal patients in analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH:5000 units of unfractionated heparin preoperatively and x3 postoperatively for seven days.<BR/>Pentosan: 50 mg preoperatively and x2 postoperatively for seven days.<BR/>Control group: No treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT.<BR/>Bleeding events:Not specified in colorectal patients.<BR/>Diagnosis: Radiofibrinogen uptake test<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>17 patients missing. No intention to treat analysis. <BR/>Unbalanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Koppenhagen-1992">
<CHAR_METHODS>
<P>RCT. Unclear randomizing procedure. Patient, surgeon and outcome-assessor blinded. <BR/>No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective surgical abdominal patients. 673 randomized patients. 20 excluded. Leaving 653 in per protocol- analysis. Subgroup of 195 colorectal patients distributed with respectively 53% and 47% in the two treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LWMH: 3000 anti Xa units (medium dose) pre- operatively and 3000 anti Xa units plus two placebo injections daily for a mean of 7.5 postoperative days.<BR/>LDH: 5000 units of unfractionated heparin pre- operatively and x3 postoperatively for a mean of 7.4 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic: DVT. PE, fatal PE and overall mortality not described in colorectal patients.<BR/>Bleeding: not specified in colorectal patients.<BR/>Diagnosis: Either radiofibrinogen uptake test or phlebography. Daily.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>20 patients missing. No intention to treat analysis.<BR/>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kosir-1996">
<CHAR_METHODS>
<P>RCT. Unclear randomizing procedure. Not blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective general surgery patients. Subgroup of 12 colorectal patients. 137 randomized patients. 29 excluded. Leaving 108 in per protocol analysis. Subgroup of Colorectal patients were distributed with respectively 17 % , 25% and 58 % in the three treatment group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intermittent compression: Intermittent compression peroperatively and for 48 hours postoperatively.<BR/>LDH: 5000 units of unfractionated heparin preoperatively and x2 postoperatively for seven days.<BR/>Control: No treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT<BR/>Bleeding events: Not described.<BR/>Diagnosis: Doppler ultrasound at 1 th, 3 th and 30 th day.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>29 missing patients. No intention to treat analysis. Unbalanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lahnborg-1974">
<CHAR_METHODS>
<P>RCT. Coded vials. Patient-, surgeon- and outcome-assessor blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective general surgery patients. 112 randomized patients. Non excluded. Leaving 112 patients in per protocol analysis as well as in intention to treat analysis. Subgroup of 19 colorectal patients were distributed with respectively 58 % and 42 % in the two treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH: 5000 U unfractionated heparin preoperatively and x2 postoperatively for five days.<BR/>Control: Placebo injection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT, PE and TE.<BR/>Bleeding events: Not described.<BR/>Diagnosis: Radiofibrinogen uptake test.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No missing patients.<BR/>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Maressi-1993">
<CHAR_METHODS>
<P>RCT. Unclear randomization procedure. Open study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective gastrointestinal patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LMWH: 3,825 I aXa Units preoperatively<BR/>Control: No treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>DVT defined as positive FUT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Half of postive FUT were verified by venography</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mcleod-2001">
<CHAR_METHODS>
<P>RCT. Computer generated randomization. Patient-, surgeon- and outcome-assesor blinded. Multicentric studie.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective colorectal patients. 1349 patients randomized. 413 excluded. Leaving 936 patients in per protocol analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH: 5000 U unfractionated heparin preoperatively and x2 postoperatively. Duration not stated.<BR/>LMWH: 40 mg enoxaparin X 1 plus saline injection X 1. Duration was up to 10 days.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT or PE<BR/>Bleeding events: Major bleeding events.<BR/>Diagnosis: Venography on 5 th to 9 th day.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>413 missing patients. No intention to treat analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Negus-1980">
<CHAR_METHODS>
<P>RCT. Sealed envelopes. Patient-, surgeon- and outcome-assessor blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective general surgery patients. 105 enrolled, 95 randomized patients. 10 patients excluded before randomizing procedure. Leaving 95 patients in per protocol analysis. Subgroup of 33 colorectal patients were distributed with respectively 42 % and 58 % in the two treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Heparin: Iv. heparin 1IU/kgxh peroperatively, the first 48 hours and uptil five days postoperatively.<BR/>Control group: Iv. saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: TE. Covering both DVT and PE.<BR/>Bleeding events: Not specified in colorectal patients.<BR/>Diagnosis: Radiofibrinogen uptake test, every second day until 6 th or 8 th postoperative day.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>10 patients missing. No intention to treat analysis.<BR/>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Nicolaides-1983">
<CHAR_METHODS>
<P>RCT. Sealed envelopes. Not blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective surgical abdominal patients. 150 randomized patients. Non excluded. Leaving 150 patients in per-protocol analysis as well as in intention to treat analysis. Subgroup of 31 colorectal patients were distributed with respectively 26%, 35% and 39 % in the three treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Electrical calf stimulation: Peroperatively.<BR/>LDH: 5000 units of unfractionated heparin preoperatively and x2 postoperatively untill discharge.<BR/>Intermittent compression/stockings: Intermittent compression peroperatively and at least for 72 hours postoperatively. When ambulant; TED- stockings.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT. PE, fatal PE and overall mortality not described.<BR/>Bleeding: Not described.<BR/>Diagnosis: Radiofibrinogen uptake test, daily</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No missing patients. 3 treatmentgroups.<BR/>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Onarheim-1986">
<CHAR_METHODS>
<P>RCT. Unclear randomizing procedure. Patient-, surgeon- and outcome-assessor blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective surgical abdominal patients. 52 randomized patients. 1 patient excluded. Leaving 51 in per protocol analysis. Subgroup of 46 colorectal patients were distributed with respectively 48% and 52% in the two treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LMWH: 5000 anti-x-activated (medium dose) units preoperatively and x1 plus placebo x1 postoperatively for six days.<BR/>LDH: 5000 U unfractionated heparin preoperatively and eigth o´cloc p.m. at the day of surgery and x2 postoperatively for six days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT<BR/>Bleeding events: Not specified in colorectal patients.<BR/>Diagnosis: Radiofibrinogen uptake test every day or every second day for at least 7 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1 missing patient.<BR/>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rem-1975">
<CHAR_METHODS>
<P>RCT. Sealed envelopes. Surgeon blinded. Not patient nor outcome-assessor blinded. (Control group = no treatment).<BR/>No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective surgical abdominal- and urological patients. 212 randomized patients. 22 excluded patients in LDH arm and 12 excluded patients in no treatment arm. Leaving 178 patients in per protocol analysis. Subgroup of 31 colorectal patients were distributed with respectively 61% and 39% in the two treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH: 5000 units of unfractionated heparin preoperatively and x3 postoperatively for at least 7 days.<BR/>Control: No treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT.<BR/>Bleeding: Not specified in colorectal patients<BR/>Diagnosis: Rradiofibrinogen uptake test, daily</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>34 patients missing. No intention to treat analysis.<BR/>Unbalanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Torngren-1978">
<CHAR_METHODS>
<P>RCT. Coded vials. Patient-, surgeon- and outcome-assessor blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective surgical abdominal patients. 175 randomized patients. From the three arm were respectively excluded 3, 4 and 1 patient. Leaving 167 patients in per protocol analysis. Subgroup of 107 colorectal patients were distributed with respectively 38%, 30% and 32 % in the three arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH: 5000 u unfrationated heparin preoperatively and x2 postoperatively for 6 to 8 days.<BR/>HDH: 25000 u unfrationated heparin preoperatively and x2 postoperatively for 6 to 8 days.<BR/>Control group: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events: DVT<BR/>Bleeding events: Not specified in colorectal patients.<BR/>Diagnosis: Radiofrbinogen uptake test performed at a mean of 10.5 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>8 missing patients. No intention to treat analysis. <BR/>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Valle-1988">
<CHAR_METHODS>
<P>RCT. Unclear randomizing procedure. Patient-, surgeon- and outcome-assessor blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective general surgery patients. 100 randomized patients. Non excluded. Leaving 100 patiens in per protocol analysis as well as in intention to treat analysis. Subgroup of 11 colorectal patients were distributed with respectively 55 % and 45 % in the two arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LMWH: 7500 anti-x-activated (highdose) preoperatively and x1 postoperatively for seven days.<BR/>Control group: Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Thromboembolic events:DVT<BR/>Bleeding events: Not specified in colorectal patients.<BR/>Diagnosis: Clinically and doppler sonography.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1986">
<CHAR_METHODS>
<P>RCT. Computergenerated list. Not blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Elective colorectal patients. 86 patients randomized. 5 excluded in LDH - and 3 excluded in LDH+TED group. Leaving 78 patients in per protocol analysis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH: 5000 U unfractionated heparin preoperatively and x2 for seven days postoperatively.<BR/>LDH+TED stockings: Same as above. Also stockings until ambulant.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tromboembolic events: DVT, PE and TE<BR/>Bleeding events: Not described.<BR/>Diagnosis: Radiofibrinogen uptake test on 1,3, 5 and 7 th postoperative day. If positive then confirmed with phlebography.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>8 patients missing. No intention to treat analysis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1991">
<CHAR_METHODS>
<P>RCT. Sealed envelopes. Not consecutive. Not blinded. No primary stratification of colorectal patients.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Acute abdominal patients. 276 randomized patients. 3 excluded in LDH arm, 15 excluded in LDH+TED arm and 13 excluded in Dextran+TED arm. Leaving 244 patients in per protocol analysis. Subgroup of 51 colorectal patients were distributed with respectively 31%, 33 % and 35% in the three treatment arms. Treatment arm with Dextran+TED were excluded from this analysis. Leaving 33 colorectal patients in analysis.</P>
<P>One arm with dextran is excluded from this analysis. Leaving 160 patients for this analysis. Of these 18 were excluded. Subgroup of 33 colorectal patients were distributed with respectively 49 % and 51 % in the two remaining treatment arms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LDH: 5000 U unfractionated heparin preoperatively and x2 for seven days postoperatively.<BR/>LDH+TED stockings: Same as above. Also stockings until ambulant.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tromboembolic events: TE<BR/>Bleeding events: Not specified in colorectal patients.<BR/>Diagnosis: Radiofibrinogen uptake test on 1,3, 5 and 7 th postoperative day. If positive then confirmed with phlebography.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>18 patients missing. No intention to treat analysis. <BR/>Balanced distribution of colorectal patients.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Bounameaux-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Colorectal patients not specified. Author contacted. Unable to help.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Browse--1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Alternate leg. Not possible to include in meta-analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Comerota-1986-A">
<CHAR_REASON_FOR_EXCLUSION>
<P>Colorectal patients not specified. Author contacted. Answered that it was not possible to recollect data. Data more than 15 years old.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ellis-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Colorectal patients not specified. Author contacted. Answered that colorectal data was never specified.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gallus-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Colorectal patients not specified. Author contacted. Answered that it was not possible to recollect data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kakkar--1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Double-publication.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mcleod--1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Possible that some of the patients in the abstract are reused in; Mcleod RS, Geerts WH, Sniderman K et al. Thromboprophylaxis after colorectal surgery - results of a randomized, double-blind comparison of low dose heparin and enoxaparin. Thrombosis and Haemostasis. juni, suppl. 1997:753 no PD3078.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-No-author-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>May contain patients from other studies.<BR/>Not possible to identify colorectal patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rasmussen--1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Fullfill all criteria but not valid diagnostic methods. Tc-plasmin test.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Strand-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>The per protocol analysis operates with 102 surgical procedures in 100 patients. It is not possible to identify the patient/patients which act as duplicates</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Torngren-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Historical controlgroup.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-T_x00f6_rngren-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Alternate leg. Not possible to include in meta-analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Adolf-1989">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bergqvist--1980">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bergqvist--1990-A">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bergqvist-1986-A">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bergqvist-1986-B">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bergqvist-1988-B">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bergqvist-1990-B">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bergqvist-1992">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bergqvist-1995">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Bergqvist-1996">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Boneu-1993">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Borow-1983">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Breddin-1983">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Buttermann-1977">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Cade-1987">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Caen-1988">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Comerota--1986-B">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Creperio-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-EFS-1988">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Encke-1988">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Enoxacan-1997">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Garcea-1992">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Gazzaniga-1993">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Gruber-1977">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Hartl-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Heather-1982">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kakkar-1972">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kakkar-1985">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kakkar-1986">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kakkar-1993">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kakkar-1997">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Koller-1986">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Kosir-1998">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lahnborg-1975">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Lareng-1978">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Leypold-1984">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Liezorovicz-1991">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Limmer-1994">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Marassi-1993">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-McLeod-1996">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Moreno-1996">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Moser-1976">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-M_x00fc_he-1984">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Negus-1982">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Nicolaides-1972">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Nurmohamed-1995">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Ockelford-1989">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Pezzuoli-1989">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Pezzuoli-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Plante-1979">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Roberts-1974">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rodiger-1991">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Rosenberg-1975">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Samama-1988">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Samama-1989">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Samama-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Samama-1994">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Schmitz-1984">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Torngren-1984">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Verardi-1988">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Zawilska-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Butson-1981">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Covey-1975">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fricker-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Gallus-1976">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Ho-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Joffe-1976">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Koppenhagen-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kosir-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lahnborg-1974">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Maressi-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mcleod-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Negus-1980">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nicolaides-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Onarheim-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rem-1975">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Torngren-1978">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Valle-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1986">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1991">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Thromboembolic events (TE). LDH vs. no treatment.</NAME>
<DICH_OUTCOME CHI2="0.36348282104281804" CI_END="0.6683846137985023" CI_START="0.13892057496598267" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3047168765383766" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.17497355611455095" LOG_CI_START="-0.8572334278948427" LOG_EFFECT_SIZE="-0.5161034920046967" METHOD="PETO" NO="1" P_CHI2="0.8338169716648113" P_Q="1.0" P_Z="0.0030241193209283234" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="71" WEIGHT="99.99999999999999" Z="2.9652755451820254">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9832889003073373" CI_START="0.1259546364179336" EFFECT_SIZE="0.35192299716273223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.007318863270987149" LOG_CI_START="-0.8997858413960078" LOG_EFFECT_SIZE="-0.45355235233349744" ORDER="979" O_E="-3.8000000000000007" SE="0.5242395207334279" STUDY_ID="STD-Gallus-1976" TOTAL_1="44" TOTAL_2="46" VAR="3.638651685393258" WEIGHT="58.44069132755728"/>
<DICH_DATA CI_END="3.057570320885996" CI_START="0.04328960205933531" EFFECT_SIZE="0.3638145165597284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4853764541372861" LOG_CI_START="-1.3636164064305287" LOG_EFFECT_SIZE="-0.43911997614662135" ORDER="980" O_E="-0.8571428571428572" SE="1.0861075589598066" STUDY_ID="STD-Joffe-1976" TOTAL_1="8" TOTAL_2="6" VAR="0.8477237048665619" WEIGHT="13.61536185671085"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="981" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosir-1996" TOTAL_1="3" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9138856081910467" CI_START="0.04680037772306184" EFFECT_SIZE="0.2068095540805866" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.039108161859713365" LOG_CI_START="-1.3297506417468279" LOG_EFFECT_SIZE="-0.6844294018032706" ORDER="982" O_E="-2.741935483870968" SE="0.7581297814690036" STUDY_ID="STD-Rem-1975" TOTAL_1="19" TOTAL_2="12" VAR="1.7398543184183144" WEIGHT="27.943946815731852"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>PE, no studies</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DVT and/or PE. Same as in "DVT".</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Thromboembolic events (TE). LDH vs. placebo</NAME>
<DICH_OUTCOME CHI2="5.3314439065448" CI_END="1.3629833514136442" CI_START="0.22476962432763134" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5534954885652282" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="62.48671025976978" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.13449055104131732" LOG_CI_START="-0.6482623802837825" LOG_EFFECT_SIZE="-0.2568859146212326" METHOD="PETO" NO="1" P_CHI2="0.06954927949319445" P_Q="1.0" P_Z="0.19828526796723" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="53" WEIGHT="100.00000000000003" Z="1.2864522651889874">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="36.08852860270091" CI_START="0.49302905636604827" EFFECT_SIZE="4.218138594525881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5573691754162673" LOG_CI_START="-0.3071274850887243" LOG_EFFECT_SIZE="0.6251208451637715" ORDER="983" O_E="1.2" SE="1.0952145677879515" STUDY_ID="STD-Covey-1975" TOTAL_1="9" TOTAL_2="11" VAR="0.8336842105263158" WEIGHT="17.62488068716092"/>
<DICH_DATA CI_END="1.453090805734147" CI_START="0.004502580317344046" EFFECT_SIZE="0.08088669891404995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.16229275483279093" LOG_CI_START="-2.3465385314638514" LOG_EFFECT_SIZE="-1.0921228883155303" ORDER="984" O_E="-1.1578947368421053" SE="1.4736999164858047" STUDY_ID="STD-Lahnborg-1974" TOTAL_1="11" TOTAL_2="8" VAR="0.46044936903662664" WEIGHT="9.734339560810124"/>
<DICH_DATA CI_END="1.2596275264074812" CI_START="0.15199758543166053" EFFECT_SIZE="0.4375618156982992" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.10024214262523533" LOG_CI_START="-0.8181633110159843" LOG_EFFECT_SIZE="-0.35896058419537447" ORDER="985" O_E="-2.84" SE="0.5394759096491677" STUDY_ID="STD-Torngren-1978" TOTAL_1="41" TOTAL_2="34" VAR="3.436021621621621" WEIGHT="72.64077975202898"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.913008824907819" CI_START="0.05198246415172601" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3891341373028486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.4643418003169786" LOG_CI_START="-1.2841431372603251" LOG_EFFECT_SIZE="-0.4099006684716732" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.3581184867743077" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="8" WEIGHT="100.0" Z="0.9189562119494702">
<NAME>PE</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9130088249078177" CI_START="0.051982464151726054" EFFECT_SIZE="0.3891341373028486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46434180031697836" LOG_CI_START="-1.2841431372603247" LOG_EFFECT_SIZE="-0.4099006684716732" ORDER="986" O_E="-0.8947368421052633" SE="1.0270687074729372" STUDY_ID="STD-Lahnborg-1974" TOTAL_1="11" TOTAL_2="8" VAR="0.9479839950754076" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.160232523605774" CI_END="0.9844950871427174" CI_START="0.21043319473263356" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.45515980313075155" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" I2="51.30053957372363" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.006786446749968473" LOG_CI_START="-0.6768857514379554" LOG_EFFECT_SIZE="-0.3418360990939619" METHOD="PETO" NO="3" P_CHI2="0.1040696113545927" P_Q="1.0" P_Z="0.0455366499869605" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="72" WEIGHT="100.0" Z="1.9996631488874355">
<NAME>DVT and/or PE.</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="36.08852860270091" CI_START="0.49302905636604827" EFFECT_SIZE="4.218138594525881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5573691754162673" LOG_CI_START="-0.3071274850887243" LOG_EFFECT_SIZE="0.6251208451637715" ORDER="987" O_E="1.2" SE="1.0952145677879515" STUDY_ID="STD-Covey-1975" TOTAL_1="9" TOTAL_2="11" VAR="0.8336842105263158" WEIGHT="12.916805347451184"/>
<DICH_DATA CI_END="2.9130088249078177" CI_START="0.051982464151726054" EFFECT_SIZE="0.3891341373028486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46434180031697836" LOG_CI_START="-1.2841431372603247" LOG_EFFECT_SIZE="-0.4099006684716732" ORDER="988" O_E="-0.8947368421052633" SE="1.0270687074729372" STUDY_ID="STD-Lahnborg-1974" TOTAL_1="11" TOTAL_2="8" VAR="0.9479839950754076" WEIGHT="14.687725378843124"/>
<DICH_DATA CI_END="0.7438315369756385" CI_START="0.021905481739463363" EFFECT_SIZE="0.12764790695681938" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.1285254123656682" LOG_CI_START="-1.6594471914933329" LOG_EFFECT_SIZE="-0.8939863019295006" ORDER="989" O_E="-2.5454545454545454" SE="0.8992710312446164" STUDY_ID="STD-Negus-1980" TOTAL_1="14" TOTAL_2="19" VAR="1.2365702479338845" WEIGHT="19.158977691238462"/>
<DICH_DATA CI_END="1.2596275264074812" CI_START="0.15199758543166053" EFFECT_SIZE="0.4375618156982992" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.10024214262523533" LOG_CI_START="-0.8181633110159843" LOG_EFFECT_SIZE="-0.35896058419537447" ORDER="990" O_E="-2.84" SE="0.5394759096491677" STUDY_ID="STD-Torngren-1978" TOTAL_1="41" TOTAL_2="34" VAR="3.436021621621621" WEIGHT="53.236491582467224"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Thromboembolic events (TE). LDH vs. no treatment or placebo</NAME>
<DICH_OUTCOME CHI2="6.652547418604884" CI_END="0.7127950824901421" CI_START="0.21809725924508594" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.39428245445933163" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="37" I2="24.840821336850276" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.14703530511983873" LOG_CI_START="-0.6613497920197152" LOG_EFFECT_SIZE="-0.404192548569777" METHOD="PETO" NO="1" P_CHI2="0.2477895662841888" P_Q="1.0" P_Z="0.002065725494443368" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="124" WEIGHT="100.00000000000001" Z="3.0806164640291014">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treat./placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="36.08852860270091" CI_START="0.49302905636604827" EFFECT_SIZE="4.218138594525881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5573691754162673" LOG_CI_START="-0.3071274850887243" LOG_EFFECT_SIZE="0.6251208451637715" ORDER="991" O_E="1.2" SE="1.0952145677879515" STUDY_ID="STD-Covey-1975" TOTAL_1="9" TOTAL_2="11" VAR="0.8336842105263158" WEIGHT="7.609117581985018"/>
<DICH_DATA CI_END="0.9832889003073373" CI_START="0.1259546364179336" EFFECT_SIZE="0.35192299716273223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.007318863270987149" LOG_CI_START="-0.8997858413960078" LOG_EFFECT_SIZE="-0.45355235233349744" ORDER="992" O_E="-3.8000000000000007" SE="0.5242395207334279" STUDY_ID="STD-Gallus-1976" TOTAL_1="44" TOTAL_2="46" VAR="3.638651685393258" WEIGHT="33.210330919624994"/>
<DICH_DATA CI_END="3.057570320885996" CI_START="0.04328960205933531" EFFECT_SIZE="0.3638145165597284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4853764541372861" LOG_CI_START="-1.3636164064305287" LOG_EFFECT_SIZE="-0.43911997614662135" ORDER="993" O_E="-0.8571428571428572" SE="1.0861075589598066" STUDY_ID="STD-Joffe-1976" TOTAL_1="8" TOTAL_2="6" VAR="0.8477237048665619" WEIGHT="7.737257424239082"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="994" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosir-1996" TOTAL_1="3" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.453090805734147" CI_START="0.004502580317344046" EFFECT_SIZE="0.08088669891404995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.16229275483279093" LOG_CI_START="-2.3465385314638514" LOG_EFFECT_SIZE="-1.0921228883155303" ORDER="995" O_E="-1.1578947368421053" SE="1.4736999164858047" STUDY_ID="STD-Lahnborg-1974" TOTAL_1="11" TOTAL_2="8" VAR="0.46044936903662664" WEIGHT="4.20256656574871"/>
<DICH_DATA CI_END="0.9138856081910467" CI_START="0.04680037772306184" EFFECT_SIZE="0.2068095540805866" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.039108161859713365" LOG_CI_START="-1.3297506417468279" LOG_EFFECT_SIZE="-0.6844294018032706" ORDER="996" O_E="-2.741935483870968" SE="0.7581297814690036" STUDY_ID="STD-Rem-1975" TOTAL_1="19" TOTAL_2="12" VAR="1.7398543184183144" WEIGHT="15.879821060796576"/>
<DICH_DATA CI_END="1.2596275264074812" CI_START="0.15199758543166053" EFFECT_SIZE="0.4375618156982992" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.10024214262523533" LOG_CI_START="-0.8181633110159843" LOG_EFFECT_SIZE="-0.35896058419537447" ORDER="997" O_E="-2.84" SE="0.5394759096491677" STUDY_ID="STD-Torngren-1978" TOTAL_1="41" TOTAL_2="34" VAR="3.436021621621621" WEIGHT="31.360906447605633"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>PE, same as LDH versus no treat/placebo</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treat/placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.065849371278937" CI_END="0.6164570602807714" CI_START="0.2006159512972006" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3516690483709118" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="43" I2="25.612297926552667" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-0.2100971690805553" LOG_CI_START="-0.6976345384894024" LOG_EFFECT_SIZE="-0.45386585378497885" METHOD="PETO" NO="3" P_CHI2="0.23331867052597077" P_Q="1.0" P_Z="2.6305806568202984E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="149" TOTAL_2="143" WEIGHT="99.99999999999999" Z="3.6492001764283164">
<NAME>DVT and/or PE.</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treat/placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="36.08852860270091" CI_START="0.49302905636604827" EFFECT_SIZE="4.218138594525881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5573691754162673" LOG_CI_START="-0.3071274850887243" LOG_EFFECT_SIZE="0.6251208451637715" ORDER="998" O_E="1.2" SE="1.0952145677879515" STUDY_ID="STD-Covey-1975" TOTAL_1="9" TOTAL_2="11" VAR="0.8336842105263158" WEIGHT="6.837425379959922"/>
<DICH_DATA CI_END="0.9832889003073373" CI_START="0.1259546364179336" EFFECT_SIZE="0.35192299716273223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.007318863270987149" LOG_CI_START="-0.8997858413960078" LOG_EFFECT_SIZE="-0.45355235233349744" ORDER="999" O_E="-3.8000000000000007" SE="0.5242395207334279" STUDY_ID="STD-Gallus-1976" TOTAL_1="44" TOTAL_2="46" VAR="3.638651685393258" WEIGHT="29.842246102796356"/>
<DICH_DATA CI_END="3.057570320885996" CI_START="0.04328960205933531" EFFECT_SIZE="0.3638145165597284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4853764541372861" LOG_CI_START="-1.3636164064305287" LOG_EFFECT_SIZE="-0.43911997614662135" ORDER="1000" O_E="-0.8571428571428572" SE="1.0861075589598066" STUDY_ID="STD-Joffe-1976" TOTAL_1="8" TOTAL_2="6" VAR="0.8477237048665619" WEIGHT="6.952569692052866"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1001" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosir-1996" TOTAL_1="3" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.453090805734147" CI_START="0.004502580317344046" EFFECT_SIZE="0.08088669891404995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.16229275483279093" LOG_CI_START="-2.3465385314638514" LOG_EFFECT_SIZE="-1.0921228883155303" ORDER="1002" O_E="-1.1578947368421053" SE="1.4736999164858047" STUDY_ID="STD-Lahnborg-1974" TOTAL_1="11" TOTAL_2="8" VAR="0.46044936903662664" WEIGHT="3.7763557978985918"/>
<DICH_DATA CI_END="0.7438315369756385" CI_START="0.021905481739463363" EFFECT_SIZE="0.12764790695681938" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.1285254123656682" LOG_CI_START="-1.6594471914933329" LOG_EFFECT_SIZE="-0.8939863019295006" ORDER="1003" O_E="-2.5454545454545454" SE="0.8992710312446164" STUDY_ID="STD-Negus-1980" TOTAL_1="14" TOTAL_2="19" VAR="1.2365702479338845" WEIGHT="10.1416779765911"/>
<DICH_DATA CI_END="0.9138856081910467" CI_START="0.04680037772306184" EFFECT_SIZE="0.2068095540805866" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.039108161859713365" LOG_CI_START="-1.3297506417468279" LOG_EFFECT_SIZE="-0.6844294018032706" ORDER="1004" O_E="-2.741935483870968" SE="0.7581297814690036" STUDY_ID="STD-Rem-1975" TOTAL_1="19" TOTAL_2="12" VAR="1.7398543184183144" WEIGHT="14.269340745551693"/>
<DICH_DATA CI_END="1.2596275264074812" CI_START="0.15199758543166053" EFFECT_SIZE="0.4375618156982992" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.10024214262523533" LOG_CI_START="-0.8181633110159843" LOG_EFFECT_SIZE="-0.35896058419537447" ORDER="1005" O_E="-2.84" SE="0.5394759096491677" STUDY_ID="STD-Torngren-1978" TOTAL_1="41" TOTAL_2="34" VAR="3.436021621621621" WEIGHT="28.18038430514947"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Thromboembolic events (TE). LMWH vs. no treatment.</NAME>
<DICH_OUTCOME CHI2="0.014899377597275776" CI_END="0.5867855663891529" CI_START="0.05297576635810776" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.17631056425336994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-0.23152057736903947" LOG_CI_START="-1.2759227519802638" LOG_EFFECT_SIZE="-0.7537216646746516" METHOD="PETO" NO="1" P_CHI2="0.9028491221997978" P_Q="1.0" P_Z="0.004670475273856206" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="187" WEIGHT="100.0" Z="2.828924245930073">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9605001308895317" CI_START="0.0274983525382" EFFECT_SIZE="0.16251821809319592" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.01750257161998929" LOG_CI_START="-1.5606933245334185" LOG_EFFECT_SIZE="-0.7890979480767039" ORDER="1006" O_E="-2.211221122112211" SE="0.9064778871787741" STUDY_ID="STD-Ho-1999" TOTAL_1="134" TOTAL_2="169" VAR="1.2169859697923107" WEIGHT="45.80325164033287"/>
<DICH_DATA CI_END="0.9671870719736846" CI_START="0.036884274388050364" EFFECT_SIZE="0.18887560283756183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.014489517159706408" LOG_CI_START="-1.433158755851133" LOG_EFFECT_SIZE="-0.7238241365054198" ORDER="1007" O_E="-2.4" SE="0.8333333333333334" STUDY_ID="STD-Maressi-1993" TOTAL_1="17" TOTAL_2="18" VAR="1.44" WEIGHT="54.19674835966713"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6179387709492823" CI_START="0.016724892215501462" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.1644987889177536" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.20896208220702364" LOG_CI_START="-1.7766366723860756" LOG_EFFECT_SIZE="-0.7838372950895259" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.12175829866748206" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="134" TOTAL_2="169" WEIGHT="100.0" Z="1.5474353663457971">
<NAME>PE</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6179387709492823" CI_START="0.016724892215501462" EFFECT_SIZE="0.1644987889177536" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.20896208220702364" LOG_CI_START="-1.7766366723860756" LOG_EFFECT_SIZE="-0.7838372950895259" ORDER="1008" O_E="-1.3267326732673268" SE="1.1663505373203398" STUDY_ID="STD-Ho-1999" TOTAL_1="134" TOTAL_2="169" VAR="0.7350921965188454" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.014899377597275776" CI_END="0.5867855663891529" CI_START="0.05297576635810776" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.17631056425336994" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.23152057736903947" LOG_CI_START="-1.2759227519802638" LOG_EFFECT_SIZE="-0.7537216646746516" METHOD="PETO" NO="3" P_CHI2="0.9028491221997978" P_Q="1.0" P_Z="0.004670475273856206" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="187" WEIGHT="100.0" Z="2.828924245930073">
<NAME>DVT and/or PE.</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9605001308895317" CI_START="0.0274983525382" EFFECT_SIZE="0.16251821809319592" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.01750257161998929" LOG_CI_START="-1.5606933245334185" LOG_EFFECT_SIZE="-0.7890979480767039" ORDER="1009" O_E="-2.211221122112211" SE="0.9064778871787741" STUDY_ID="STD-Ho-1999" TOTAL_1="134" TOTAL_2="169" VAR="1.2169859697923107" WEIGHT="45.80325164033287"/>
<DICH_DATA CI_END="0.9671870719736846" CI_START="0.036884274388050364" EFFECT_SIZE="0.18887560283756183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.014489517159706408" LOG_CI_START="-1.433158755851133" LOG_EFFECT_SIZE="-0.7238241365054198" ORDER="1010" O_E="-2.4" SE="0.8333333333333334" STUDY_ID="STD-Maressi-1993" TOTAL_1="17" TOTAL_2="18" VAR="1.44" WEIGHT="54.19674835966713"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" NO="5">
<NAME>Thromboembolic events (TE). LMWH vs. placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.675888506745636" CI_START="0.0021630692513563573" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.11080315836233387" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.7540338558867912" LOG_CI_START="-2.6649295762610996" LOG_EFFECT_SIZE="-0.9554478601871541" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.2733216954331794" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="6" TOTAL_2="5" WEIGHT="100.0" Z="1.0954451150103324">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.675888506745636" CI_START="0.0021630692513563573" EFFECT_SIZE="0.11080315836233387" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7540338558867912" LOG_CI_START="-2.6649295762610996" LOG_EFFECT_SIZE="-0.9554478601871541" ORDER="1011" O_E="-0.5454545454545454" SE="2.008316044185609" STUDY_ID="STD-Valle-1988" TOTAL_1="6" TOTAL_2="5" VAR="0.24793388429752064" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>PE, no studies</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DVT and/or PE. Same as in "DVT".</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" NO="6">
<NAME>Thromboembolic events (TE). LMWH vs. no treatment or placebo</NAME>
<DICH_OUTCOME CHI2="0.06382619470303719" CI_END="0.5351559760632996" CI_START="0.05365890080083567" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.16945760954455535" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="-0.271519620462905" LOG_CI_START="-1.2703582280677521" LOG_EFFECT_SIZE="-0.7709389242653286" METHOD="PETO" NO="1" P_CHI2="0.9685907517920803" P_Q="1.0" P_Z="0.0024819048505465716" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="157" TOTAL_2="192" WEIGHT="100.0" Z="3.0255388895377413">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treat/placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9605001308895317" CI_START="0.0274983525382" EFFECT_SIZE="0.16251821809319592" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.01750257161998929" LOG_CI_START="-1.5606933245334185" LOG_EFFECT_SIZE="-0.7890979480767039" ORDER="1012" O_E="-2.211221122112211" SE="0.9064778871787741" STUDY_ID="STD-Ho-1999" TOTAL_1="134" TOTAL_2="169" VAR="1.2169859697923107" WEIGHT="41.89396027841933"/>
<DICH_DATA CI_END="0.9671870719736846" CI_START="0.036884274388050364" EFFECT_SIZE="0.18887560283756183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.014489517159706408" LOG_CI_START="-1.433158755851133" LOG_EFFECT_SIZE="-0.7238241365054198" ORDER="1013" O_E="-2.4" SE="0.8333333333333334" STUDY_ID="STD-Maressi-1993" TOTAL_1="17" TOTAL_2="18" VAR="1.44" WEIGHT="49.57107501512052"/>
<DICH_DATA CI_END="5.675888506745636" CI_START="0.0021630692513563573" EFFECT_SIZE="0.11080315836233387" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7540338558867912" LOG_CI_START="-2.6649295762610996" LOG_EFFECT_SIZE="-0.9554478601871541" ORDER="1014" O_E="-0.5454545454545454" SE="2.008316044185609" STUDY_ID="STD-Valle-1988" TOTAL_1="6" TOTAL_2="5" VAR="0.24793388429752064" WEIGHT="8.534964706460144"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>PE, same as LMWH versus no treatment</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DVT and/or PE, same as LMWH versus no treatment or placebo / DVT</NAME>
<GROUP_LABEL_1>LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Thromboembolic events (TE). LDH or LMWH vs. no treatment or placebo</NAME>
<DICH_OUTCOME CHI2="8.353794637696033" CI_END="0.559212329387218" CI_START="0.1951280749556283" CI_STUDY="95" CI_TOTAL="95" DF="8.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.33033017622491073" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="49" I2="4.235136881382681" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="-0.2524232619301052" LOG_CI_START="-0.70968023997955" LOG_EFFECT_SIZE="-0.48105175095482766" METHOD="PETO" NO="1" P_CHI2="0.39969537015392576" P_Q="1.0" P_Z="3.7248886936484055E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="292" TOTAL_2="316" WEIGHT="100.00000000000001" Z="4.123913474621445">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LDH or LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treat. and Placeb</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="36.08852860270091" CI_START="0.49302905636604827" EFFECT_SIZE="4.218138594525881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5573691754162673" LOG_CI_START="-0.3071274850887243" LOG_EFFECT_SIZE="0.6251208451637715" ORDER="1015" O_E="1.2" SE="1.0952145677879515" STUDY_ID="STD-Covey-1975" TOTAL_1="9" TOTAL_2="11" VAR="0.8336842105263158" WEIGHT="6.014471398784772"/>
<DICH_DATA CI_END="0.9832889003073373" CI_START="0.1259546364179336" EFFECT_SIZE="0.35192299716273223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.007318863270987149" LOG_CI_START="-0.8997858413960078" LOG_EFFECT_SIZE="-0.45355235233349744" ORDER="1016" O_E="-3.8000000000000007" SE="0.5242395207334279" STUDY_ID="STD-Gallus-1976" TOTAL_1="44" TOTAL_2="46" VAR="3.638651685393258" WEIGHT="26.25042697896574"/>
<DICH_DATA CI_END="0.9605001308895317" CI_START="0.0274983525382" EFFECT_SIZE="0.16251821809319592" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.01750257161998929" LOG_CI_START="-1.5606933245334185" LOG_EFFECT_SIZE="-0.7890979480767039" ORDER="1017" O_E="-2.211221122112211" SE="0.9064778871787741" STUDY_ID="STD-Ho-1999" TOTAL_1="134" TOTAL_2="169" VAR="1.2169859697923107" WEIGHT="8.779736038682184"/>
<DICH_DATA CI_END="3.057570320885996" CI_START="0.04328960205933531" EFFECT_SIZE="0.3638145165597284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4853764541372861" LOG_CI_START="-1.3636164064305287" LOG_EFFECT_SIZE="-0.43911997614662135" ORDER="1018" O_E="-0.8571428571428572" SE="1.0861075589598066" STUDY_ID="STD-Joffe-1976" TOTAL_1="8" TOTAL_2="6" VAR="0.8477237048665619" WEIGHT="6.115756916846224"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1019" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosir-1996" TOTAL_1="3" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.453090805734147" CI_START="0.004502580317344046" EFFECT_SIZE="0.08088669891404995" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.16229275483279093" LOG_CI_START="-2.3465385314638514" LOG_EFFECT_SIZE="-1.0921228883155303" ORDER="1020" O_E="-1.1578947368421053" SE="1.4736999164858047" STUDY_ID="STD-Lahnborg-1974" TOTAL_1="11" TOTAL_2="8" VAR="0.46044936903662664" WEIGHT="3.321832806346365"/>
<DICH_DATA CI_END="0.9671870719736846" CI_START="0.036884274388050364" EFFECT_SIZE="0.18887560283756183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.014489517159706408" LOG_CI_START="-1.433158755851133" LOG_EFFECT_SIZE="-0.7238241365054198" ORDER="1021" O_E="-2.4" SE="0.8333333333333334" STUDY_ID="STD-Maressi-1993" TOTAL_1="17" TOTAL_2="18" VAR="1.44" WEIGHT="10.388632416082787"/>
<DICH_DATA CI_END="0.9138856081910467" CI_START="0.04680037772306184" EFFECT_SIZE="0.2068095540805866" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.039108161859713365" LOG_CI_START="-1.3297506417468279" LOG_EFFECT_SIZE="-0.6844294018032706" ORDER="1022" O_E="-2.741935483870968" SE="0.7581297814690036" STUDY_ID="STD-Rem-1975" TOTAL_1="19" TOTAL_2="12" VAR="1.7398543184183144" WEIGHT="12.551879841376476"/>
<DICH_DATA CI_END="1.2596275264074812" CI_START="0.15199758543166053" EFFECT_SIZE="0.4375618156982992" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.10024214262523533" LOG_CI_START="-0.8181633110159843" LOG_EFFECT_SIZE="-0.35896058419537447" ORDER="1023" O_E="-2.84" SE="0.5394759096491677" STUDY_ID="STD-Torngren-1978" TOTAL_1="41" TOTAL_2="34" VAR="3.436021621621621" WEIGHT="24.788587222735917"/>
<DICH_DATA CI_END="5.675888506745636" CI_START="0.0021630692513563573" EFFECT_SIZE="0.11080315836233387" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7540338558867912" LOG_CI_START="-2.6649295762610996" LOG_EFFECT_SIZE="-0.9554478601871541" ORDER="1024" O_E="-0.5454545454545454" SE="2.008316044185609" STUDY_ID="STD-Valle-1988" TOTAL_1="6" TOTAL_2="5" VAR="0.24793388429752064" WEIGHT="1.7886763801795431"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3069491464602089" CI_END="1.2103094119547075" CI_START="0.05897456642553992" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.26716562804892974" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="0.08289641058645249" LOG_CI_START="-1.2293352433154094" LOG_EFFECT_SIZE="-0.5732194163644784" METHOD="PETO" NO="2" P_CHI2="0.5795584747673643" P_Q="1.0" P_Z="0.08683514195588483" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="145" TOTAL_2="177" WEIGHT="100.0" Z="1.712333958676888">
<NAME>PE</NAME>
<GROUP_LABEL_1>LDH or LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treat/placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6179387709492823" CI_START="0.016724892215501462" EFFECT_SIZE="0.1644987889177536" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.20896208220702364" LOG_CI_START="-1.7766366723860756" LOG_EFFECT_SIZE="-0.7838372950895259" ORDER="1025" O_E="-1.3267326732673268" SE="1.1663505373203398" STUDY_ID="STD-Ho-1999" TOTAL_1="134" TOTAL_2="169" VAR="0.7350921965188454" WEIGHT="43.675515118691514"/>
<DICH_DATA CI_END="2.9130088249078177" CI_START="0.051982464151726054" EFFECT_SIZE="0.3891341373028486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46434180031697836" LOG_CI_START="-1.2841431372603247" LOG_EFFECT_SIZE="-0.4099006684716732" ORDER="1026" O_E="-0.8947368421052633" SE="1.0270687074729372" STUDY_ID="STD-Lahnborg-1974" TOTAL_1="11" TOTAL_2="8" VAR="0.9479839950754076" WEIGHT="56.32448488130848"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.576673549042999" CI_END="0.5298812999729087" CI_START="0.19631533804331533" CI_STUDY="95" CI_TOTAL="95" DF="9.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.3225272492782787" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="56" I2="0.0" I2_Q="0.0" ID="CMP-007.03" LOG_CI_END="-0.2758214068904263" LOG_CI_START="-0.7070457678103419" LOG_EFFECT_SIZE="-0.4914335873503841" METHOD="PETO" NO="3" P_CHI2="0.47723127616378025" P_Q="1.0" P_Z="7.923389060261443E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="306" TOTAL_2="335" WEIGHT="99.99999999999999" Z="4.467243594240958">
<NAME>DVT and/or PE.</NAME>
<GROUP_LABEL_1>LDH or LMWH</GROUP_LABEL_1>
<GROUP_LABEL_2>No treat/placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="36.08852860270091" CI_START="0.49302905636604827" EFFECT_SIZE="4.218138594525881" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.5573691754162673" LOG_CI_START="-0.3071274850887243" LOG_EFFECT_SIZE="0.6251208451637715" ORDER="1027" O_E="1.2" SE="1.0952145677879515" STUDY_ID="STD-Covey-1975" TOTAL_1="9" TOTAL_2="11" VAR="0.8336842105263158" WEIGHT="5.349132489258716"/>
<DICH_DATA CI_END="0.9832889003073373" CI_START="0.1259546364179336" EFFECT_SIZE="0.35192299716273223" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.007318863270987149" LOG_CI_START="-0.8997858413960078" LOG_EFFECT_SIZE="-0.45355235233349744" ORDER="1028" O_E="-3.8000000000000007" SE="0.5242395207334279" STUDY_ID="STD-Gallus-1976" TOTAL_1="44" TOTAL_2="46" VAR="3.638651685393258" WEIGHT="23.346525820784606"/>
<DICH_DATA CI_END="0.9605001308895317" CI_START="0.0274983525382" EFFECT_SIZE="0.16251821809319592" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.01750257161998929" LOG_CI_START="-1.5606933245334185" LOG_EFFECT_SIZE="-0.7890979480767039" ORDER="1029" O_E="-2.211221122112211" SE="0.9064778871787741" STUDY_ID="STD-Ho-1999" TOTAL_1="134" TOTAL_2="169" VAR="1.2169859697923107" WEIGHT="7.808495240515999"/>
<DICH_DATA CI_END="3.057570320885996" CI_START="0.04328960205933531" EFFECT_SIZE="0.3638145165597284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.4853764541372861" LOG_CI_START="-1.3636164064305287" LOG_EFFECT_SIZE="-0.43911997614662135" ORDER="1030" O_E="-0.8571428571428572" SE="1.0861075589598066" STUDY_ID="STD-Joffe-1976" TOTAL_1="8" TOTAL_2="6" VAR="0.8477237048665619" WEIGHT="5.43921349878241"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1031" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosir-1996" TOTAL_1="3" TOTAL_2="7" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.9130088249078177" CI_START="0.051982464151726054" EFFECT_SIZE="0.3891341373028486" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.46434180031697836" LOG_CI_START="-1.2841431372603247" LOG_EFFECT_SIZE="-0.4099006684716732" ORDER="1032" O_E="-0.8947368421052633" SE="1.0270687074729372" STUDY_ID="STD-Lahnborg-1974" TOTAL_1="11" TOTAL_2="8" VAR="0.9479839950754076" WEIGHT="6.0825093282668945"/>
<DICH_DATA CI_END="0.9671870719736846" CI_START="0.036884274388050364" EFFECT_SIZE="0.18887560283756183" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="-0.014489517159706408" LOG_CI_START="-1.433158755851133" LOG_EFFECT_SIZE="-0.7238241365054198" ORDER="1033" O_E="-2.4" SE="0.8333333333333334" STUDY_ID="STD-Maressi-1993" TOTAL_1="17" TOTAL_2="18" VAR="1.44" WEIGHT="9.239410663265055"/>
<DICH_DATA CI_END="0.7438315369756385" CI_START="0.021905481739463363" EFFECT_SIZE="0.12764790695681938" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="6" LOG_CI_END="-0.1285254123656682" LOG_CI_START="-1.6594471914933329" LOG_EFFECT_SIZE="-0.8939863019295006" ORDER="1034" O_E="-2.5454545454545454" SE="0.8992710312446164" STUDY_ID="STD-Negus-1980" TOTAL_1="14" TOTAL_2="19" VAR="1.2365702479338845" WEIGHT="7.934153010164336"/>
<DICH_DATA CI_END="0.9138856081910467" CI_START="0.04680037772306184" EFFECT_SIZE="0.2068095540805866" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="-0.039108161859713365" LOG_CI_START="-1.3297506417468279" LOG_EFFECT_SIZE="-0.6844294018032706" ORDER="1035" O_E="-2.741935483870968" SE="0.7581297814690036" STUDY_ID="STD-Rem-1975" TOTAL_1="19" TOTAL_2="12" VAR="1.7398543184183144" WEIGHT="11.16335315425134"/>
<DICH_DATA CI_END="1.2596275264074812" CI_START="0.15199758543166053" EFFECT_SIZE="0.4375618156982992" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.10024214262523533" LOG_CI_START="-0.8181633110159843" LOG_EFFECT_SIZE="-0.35896058419537447" ORDER="1036" O_E="-2.84" SE="0.5394759096491677" STUDY_ID="STD-Torngren-1978" TOTAL_1="41" TOTAL_2="34" VAR="3.436021621621621" WEIGHT="22.046399173625062"/>
<DICH_DATA CI_END="5.675888506745636" CI_START="0.0021630692513563573" EFFECT_SIZE="0.11080315836233387" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7540338558867912" LOG_CI_START="-2.6649295762610996" LOG_EFFECT_SIZE="-0.9554478601871541" ORDER="1037" O_E="-0.5454545454545454" SE="2.008316044185609" STUDY_ID="STD-Valle-1988" TOTAL_1="6" TOTAL_2="5" VAR="0.24793388429752064" WEIGHT="1.5908076210855808"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" NO="8">
<NAME>Thromboembolic events (TE). LDH vs. LMWH</NAME>
<DICH_OUTCOME CHI2="0.0407432060756336" CI_END="1.5205247766073167" CI_START="0.6745607862835048" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.012761763136712" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-008.01" LOG_CI_END="0.18199350126816063" LOG_CI_START="-0.1709789089156934" LOG_EFFECT_SIZE="0.005507296176233557" METHOD="PETO" NO="1" P_CHI2="0.9798345032311001" P_Q="1.0" P_Z="0.9512308565253101" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="584" TOTAL_2="593" WEIGHT="100.0" Z="0.061161166403859456">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.6216905880041987" CI_START="0.3509985532891031" EFFECT_SIZE="1.1274786724591446" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.558911344469945" LOG_CI_START="-0.4546946735622507" LOG_EFFECT_SIZE="0.05210833545384714" ORDER="1038" O_E="0.33846153846153815" SE="0.5953971924228211" STUDY_ID="STD-Koppenhagen-1992" TOTAL_1="92" TOTAL_2="103" VAR="2.82089184407979" WEIGHT="12.12671469486382"/>
<DICH_DATA CI_END="1.5508106333151155" CI_START="0.6448240542833613" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="44" LOG_CI_END="0.1905587701364666" LOG_CI_START="-0.19055877013646663" LOG_EFFECT_SIZE="0.0" ORDER="1039" O_E="0.0" SE="0.22387032971857143" STUDY_ID="STD-Mcleod-2001" TOTAL_1="468" TOTAL_2="468" VAR="19.95294117647059" WEIGHT="85.77557678372841"/>
<DICH_DATA CI_END="15.130014493108787" CI_START="0.05530549739239233" EFFECT_SIZE="0.9147529595991949" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1798393440360193" LOG_CI_START="-1.2572316974743571" LOG_EFFECT_SIZE="-0.03869617671916885" ORDER="1040" O_E="-0.04347826086956519" SE="1.4315475934794113" STUDY_ID="STD-Onarheim-1986" TOTAL_1="24" TOTAL_2="22" VAR="0.48796471329552615" WEIGHT="2.097708521407775"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.820467167072353" CI_START="0.0026853936013588454" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-008.02" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.31731052126128756" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="470" TOTAL_2="472" WEIGHT="100.0" Z="1.0">
<NAME>PE</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1041" O_E="0.0" SE="0.0" STUDY_ID="STD-Fricker-1988" TOTAL_1="2" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.820467167072353" CI_START="0.0026853936013588454" EFFECT_SIZE="0.1353352832366127" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8338141226232083" LOG_CI_START="-2.570992050236215" LOG_EFFECT_SIZE="-0.8685889638065036" ORDER="1042" O_E="-0.5" SE="2.0" STUDY_ID="STD-Mcleod-2001" TOTAL_1="468" TOTAL_2="468" VAR="0.25" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0407432060756336" CI_END="1.5205247766073167" CI_START="0.6745607862835048" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.012761763136712" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="51" I2="0.0" I2_Q="0.0" ID="CMP-008.03" LOG_CI_END="0.18199350126816063" LOG_CI_START="-0.1709789089156934" LOG_EFFECT_SIZE="0.005507296176233557" METHOD="PETO" NO="3" P_CHI2="0.9798345032311001" P_Q="1.0" P_Z="0.9512308565253101" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="586" TOTAL_2="597" WEIGHT="100.0" Z="0.061161166403859456">
<NAME>DVT and PE.</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>LMWH</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1043" O_E="0.0" SE="0.0" STUDY_ID="STD-Fricker-1988" TOTAL_1="2" TOTAL_2="4" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.6216905880041987" CI_START="0.3509985532891031" EFFECT_SIZE="1.1274786724591446" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.558911344469945" LOG_CI_START="-0.4546946735622507" LOG_EFFECT_SIZE="0.05210833545384714" ORDER="1044" O_E="0.33846153846153815" SE="0.5953971924228211" STUDY_ID="STD-Koppenhagen-1992" TOTAL_1="92" TOTAL_2="103" VAR="2.82089184407979" WEIGHT="12.12671469486382"/>
<DICH_DATA CI_END="1.5508106333151155" CI_START="0.6448240542833613" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="44" LOG_CI_END="0.1905587701364666" LOG_CI_START="-0.19055877013646663" LOG_EFFECT_SIZE="0.0" ORDER="1045" O_E="0.0" SE="0.22387032971857143" STUDY_ID="STD-Mcleod-2001" TOTAL_1="468" TOTAL_2="468" VAR="19.95294117647059" WEIGHT="85.77557678372841"/>
<DICH_DATA CI_END="15.130014493108787" CI_START="0.05530549739239233" EFFECT_SIZE="0.9147529595991949" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1798393440360193" LOG_CI_START="-1.2572316974743571" LOG_EFFECT_SIZE="-0.03869617671916885" ORDER="1046" O_E="-0.04347826086956519" SE="1.4315475934794113" STUDY_ID="STD-Onarheim-1986" TOTAL_1="24" TOTAL_2="22" VAR="0.48796471329552615" WEIGHT="2.097708521407775"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" NO="9">
<NAME>Thromboembolic events (TE). LDH versus IPC</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3" TOTAL_2="2" WEIGHT="0.0" Z="0.0">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>Inter. compre.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1047" O_E="0.0" SE="0.0" STUDY_ID="STD-Kosir-1996" TOTAL_1="3" TOTAL_2="2" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>PE, no studies</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>Inter. compre.</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-009.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DVT and/or PE. Same as in "DVT".</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>IPC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" NO="10">
<NAME>Thromboembolic events (TE). LDH vs. LDH+TED</NAME>
<DICH_OUTCOME CHI2="0.015275264069990135" CI_END="16.01230581943393" CI_START="1.3333947131874977" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.620684356843108" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="1.2044538761135748" LOG_CI_START="0.12495872884710592" LOG_EFFECT_SIZE="0.6647063024803403" METHOD="PETO" NO="1" P_CHI2="0.9016374282479772" P_Q="1.0" P_Z="0.015790519597284107" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="59" WEIGHT="100.00000000000001" Z="2.4137216669426373">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>LDH+TED stockings</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="26.0437641728362" CI_START="0.941827934016888" EFFECT_SIZE="4.952650260711467" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.4157037541414685" LOG_CI_START="-0.02602843280444256" LOG_EFFECT_SIZE="0.6948376606685129" ORDER="1048" O_E="2.230769230769231" SE="0.8468806233014526" STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1986" TOTAL_1="36" TOTAL_2="42" VAR="1.394298009682625" WEIGHT="56.06246640944862"/>
<DICH_DATA CI_END="27.5764426981592" CI_START="0.6486070151142114" EFFECT_SIZE="4.2292167343281335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.440538242398167" LOG_CI_START="-0.18801835845534293" LOG_EFFECT_SIZE="0.6262599419714119" ORDER="1049" O_E="1.5757575757575757" SE="0.9566222088265398" STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1991" TOTAL_1="16" TOTAL_2="17" VAR="1.0927456382001837" WEIGHT="43.937533590551396"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="14.160591063734927" CI_START="0.6411058198981369" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.013044530729344" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-010.02" LOG_CI_END="1.1510813812041183" LOG_CI_START="-0.19307028061404757" LOG_EFFECT_SIZE="0.4790055502950354" METHOD="PETO" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.16243876743777258" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="59" WEIGHT="100.0" Z="1.396916216586968">
<NAME>PE</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>LDH+TED stockings</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.160591063734927" CI_START="0.6411058198981369" EFFECT_SIZE="3.013044530729344" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.1510813812041183" LOG_CI_START="-0.19307028061404757" LOG_EFFECT_SIZE="0.4790055502950354" ORDER="1050" O_E="1.7692307692307692" SE="0.7895613398100254" STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1986" TOTAL_1="36" TOTAL_2="42" VAR="1.6040882194728348" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1051" O_E="0.0" SE="0.0" STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1991" TOTAL_1="16" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4213354895658993E-4" CI_END="12.698668390282533" CI_START="1.3689817699757079" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.169441872632782" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="1.103758182288812" LOG_CI_START="0.1363976648968319" LOG_EFFECT_SIZE="0.620077923592822" METHOD="PETO" NO="3" P_CHI2="0.9852424886677968" P_Q="1.0" P_Z="0.011982029049232837" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="52" TOTAL_2="59" WEIGHT="100.0" Z="2.5126731471878996">
<NAME>DVT and/or PE.</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>LDH+TED stockings</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.517768432093643" CI_START="1.0362477594844004" EFFECT_SIZE="4.137209268267584" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.217951373305678" LOG_CI_START="0.01546360455267163" LOG_EFFECT_SIZE="0.6167074889291748" ORDER="1052" O_E="2.846153846153846" SE="0.7063472677759706" STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1986" TOTAL_1="36" TOTAL_2="42" VAR="2.0043033889187734" WEIGHT="64.71655344711431"/>
<DICH_DATA CI_END="27.5764426981592" CI_START="0.6486070151142114" EFFECT_SIZE="4.2292167343281335" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.440538242398167" LOG_CI_START="-0.18801835845534293" LOG_EFFECT_SIZE="0.6262599419714119" ORDER="1053" O_E="1.5757575757575757" SE="0.9566222088265398" STUDY_ID="STD-Wille_x002d_J_x00f8_rgensen-1991" TOTAL_1="16" TOTAL_2="17" VAR="1.0927456382001837" WEIGHT="35.2834465528857"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" NO="11">
<NAME>Thromboembolic events (TE). LDH vs. TED + IPC</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="107.32707601365593" CI_START="0.9269265439531382" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="9.974182454814724" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="2.030709297734335" LOG_CI_START="-0.032954680979376344" LOG_EFFECT_SIZE="0.9988773083774793" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.057779571125595876" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="12" WEIGHT="100.0" Z="1.8973665961010278">
<NAME>DVT</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>TED+ IPC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="107.32707601365593" CI_START="0.9269265439531382" EFFECT_SIZE="9.974182454814724" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.030709297734335" LOG_CI_START="-0.032954680979376344" LOG_EFFECT_SIZE="0.9988773083774793" ORDER="1054" O_E="1.565217391304348" SE="1.2122064363978788" STUDY_ID="STD-Nicolaides-1983" TOTAL_1="11" TOTAL_2="12" VAR="0.6805293005671077" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>PE, no studies</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>TED stockings</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DVT and/or PE. Same as in "DVT".</NAME>
<GROUP_LABEL_1>LDH</GROUP_LABEL_1>
<GROUP_LABEL_2>TED stockings + IPC</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" NO="12">
<NAME>Thromboembolic events (TE). IPC vs. no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.691761392790248" CI_START="0.030665255843744344" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5725954929356162" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="1.0290492580763784" LOG_CI_START="-1.513353407592732" LOG_EFFECT_SIZE="-0.2421520747581768" METHOD="PETO" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7088842641490166" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="9" WEIGHT="100.0" Z="0.37335497772755005">
<NAME>DVT</NAME>
<GROUP_LABEL_1>Intermittent compres</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.691761392790248" CI_START="0.030665255843744344" EFFECT_SIZE="0.5725954929356162" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0290492580763784" LOG_CI_START="-1.513353407592732" LOG_EFFECT_SIZE="-0.2421520747581768" ORDER="1055" O_E="-0.25" SE="1.4934199109102002" STUDY_ID="STD-Butson-1981" TOTAL_1="15" TOTAL_2="9" VAR="0.4483695652173913" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>PE, no studies</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-012.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>DVT and/or PE. Same as in "DVT".</NAME>
<GROUP_LABEL_1>IPC</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2008-07-24 16:09:13 +0200" MODIFIED_BY="[Empty name]">
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Safety and effectiveness of thromboprophylaxis</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>Submitted by David Cundiff, MD, July 11 2007 - Email Address: dkcundiff3@verizon.net</P>
<P>The conclusions of this review are based on surrogate endpoints (bilateral venography and noninvasive DVT assessment tests) rather than clinical endpoints (total mortality, pulmonary embolism fatalities, symptomatic venous thromboembolism). The small number of patients involved in the studies (&lt; 2,000) made it impossible to reach meaningful conclusions about safety (e.g., bleeding and heparin induced thrombocytopenia with thrombosis) and efficacy. The called for large randomized trials with fatal pulmonary embolism as outcome will probably never be done. Since fatal pulmonary emboli occurs in only about 1-2 cases per 10,000 hospital discharges,1 it would take over 200,000 subjects to do such a trial. The closest study to such a mammoth RTC was a retrospective analysis of about 80,000 hospitalized patients reported by Goldhaber and colleagues in 2000 (1). They looked for the development of VTE during the index hospitalization and up to 30 days after discharge. Of the 384 VTE cases found, 201 had received prophylaxis and 183 had not. Twelve of the 13 fatal pulmonary emboli (FPE) cases occurred in patients receiving anticoagulant prophylaxis.<BR/>Goldhaber's study provides evidence that will never be found in RCTs with n &lt; 20,000 (i.e., all reported RCTs): anticoagulant prophylaxis very likely increases the risk of death. A possible mechanism is rebound hypercoagulation.<BR/>Neither heparin nor LMWHs are evidence-based to be safe or effective as thromboprophylaxis after colorectal surgery (2;3).</P>
<P>Undisclosed financial conflict of interest:<BR/>Dr. Wille-Jorgensen has received research funding from Novartis (4) and co-authored a Pfizer-funded dalteparin (Fragmin) thromboprophylaxis trial (5).</P>
<P>Reference list:<BR/>1.   Goldhaber SZ, Dunn K, MacDougall RC. New Onset of Venous Thromboembolism Among Hospitalized Patients at Brigham and Women's Hospital Is Caused More Often by Prophylaxis Failure Than by Withholding Treatment. Chest. 2000;118:1680-1684.<BR/>2.   Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants--a prospective study. Thromb Haemost.<BR/>1994;72(2):222-226.<BR/>3.   Cundiff DK. Commentary - Insufficient Evidence Supporting Low-Intensity Warfarin for Venous Thromboembolism (VTE) Prophylaxis. Medscape General Medicine. 07/02/2003;http://www.medscape. com/viewarticle/457570.<BR/>4.   Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. New England Journal of Medicine. 1997;337(19):1329-1335.<BR/>5.   Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost. 2006; 4(11):2384-2390.</P>
<P>Submitter agrees with default conflict of interest statement: I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>Submitted by contact author Peer Wille-Jørgensen, July 17 2007</P>
<P>The discussion on surrogate end-points in research on thrombosis prophylaxis has been long. In my opinion there is overwhelming evidence, that if you lower the incidence of subclinical DVT, you will also lower the incidence of clinical DVT and Fatal PE (1) - but for statistical reasons it might be difficult to lower the total postoperative mortality. Also an indirect proof of the relation between subclinical DVT and later postphlebitic syndrome has been established (2) Latest evidence is seen in the research on the efficacy of long-term postoperative prophylaxis, in which the same trials the extended prophylaxis lower the incidence of both subclinical and clinical DVT (3;4). <BR/>As the diagnosis of pulmonary embolism very seldom is established before death (5) retrospective analysis of incidences of postoperative fatal PE is of very little value even thoug the number of patients is large. Another investigation from one department found although an association between fatal PE and omission of prophylaxis(6).<BR/>I agree, that a prospective randomised trial with total mortality as endpoint is unfeasible. We must not althoug forget that the efficacy of heparin prophylaxis against fatal Postoperative PE was established in a methodologically correctly performed trial more than 30 years ago(7).<BR/>Taken these facts in mind I still mean that the use of postoperative prophylaxis is evidence based, and for comparing different methods the use of venography for detecting subclinical DVT as endpoint is scientifically acceptable.</P>
<P>Concerning my conflict of interest. I have participtated in several partly industry-sponsored trials on thrombosis prophylaxis, but never have gained any personal financial benefits from it.</P>
<P>Peer Wille-Jørgensen</P>
<P>Reference List</P>
<P>(1) Kakkar VV. Fibrinogen Uptake Test for Detection of Deep Vein Thrombosis - A review of Current Practice. Sem Nucl Med 1977; 7:229-244.<BR/>(2) Wille-Jorgensen P, Jorgensen LN, Crawford M. Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A systematic review and meta-analysis. Thromb Haemost 2005; 93(2):236-241.<BR/>(3) Hull RD, Pineo GF, Stein PD, Mah AF, MacIsaac SM, Dahl OE et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A systematic review. Ann Int Med 2001; 135(10):858-869.<BR/>(4) Dahl OE. Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now? Haemostasis 2000; 30 Suppl 2:101-105.<BR/>(5) Hauch O, Jorgensen LN, Khattar SC, Teglbjaerg CS, Wahlin AB, Rathenborg P et al. Fatal pulmonary embolism associated with surgery. An autopsy study. Acta Chir Scand 1990; 156(11-12):747-749.<BR/>(6) Rasmussen MS, Wille-Jorgensen P, Jorgensen LN. Postoperative fatal pulmonary embolism in a general surgical department. Am J Surg 1995; 169(2):214-216.<BR/>(7) Kakkar VV, Corrigan TP, Fossard DP, Sutherland I, Thiewell J. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraissal of Results of International Multicenter Trial. Lancet 1977; i:567-569.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>David Cundiff and Peer Wille-Jørgensen</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
<FEEDBACK_ITEM ID="FBK-02" MODIFIED="2008-07-24 16:09:13 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-07-24 16:08:38 +0200" MODIFIED_BY="[Empty name]">Cundiff reply to the 2007 feedback from authors</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2008-07-24 16:07:07 +0200" MODIFIED_BY="[Empty name]">
<P>Date of Submission: 22-Jul-2008<BR/>Name: David K. Cundiff, MD<BR/>Email Address: dkcundiff3@verizon.net<BR/>Personal Description: Occupation Physician<BR/>
<BR/>Feedback: I thank Dr. Wille-J?rgensen for the reply.<BR/>
<BR/>The clinical relevance of the surrogate endpoint of asymptomatic DVT prevention with anticoagulants correlating with a lower incidence of clinical DVT and fatal PE is hardly settled by Kakkar?s 1977 article in the Seminars of Nuclear Medicine, ?Fibrinogen Uptake Test for Detection of Deep Vein Thrombosis? review?1 (reference 1 of the reply).<BR/>
<BR/>While you have demonstrated a positive correlation between asymptomatic post operative DVT with later postphlebitic syndrome,2 this does not prove that post phlebitic syndrome is prevented by prophylactic anticoagulants. It may be that rebound hypercoagulation related DVT after stopping heparin increases VTE and subsequently the post phlebitic syndrome.<BR/>
<BR/>Regarding the efficacy of long-term postoperative prophylaxis with orthopaedic procedures, RCTs comparing heparins for 6-10 days post op versus extending the prophylaxis for an additional 3-4 weeks at home generally do not have data on outcomes after the completion of the extended prophylaxis. This misses outcome events due to post heparin rebound hypercoagulability. In the six RCTs reviewed by Hull and colleagues,3 none had an unanticoagulated arm to see the effect of short term prophylaxis itself. This meta-analysis included only 1953 patients and fatal PE occurred in only 2/862 placebo-treated patients (possibly due to rebound hypercoagulability) versus 0/1091 who received extended prophylaxis. This makes the Goldhaber study,4 about which Dr. Wille-J?rgensen had no comment, particularly relevant. Out of about 80,000 hospitalizations of patients followed for at least 2 months (i.e., capturing rebound hypercoagulability events), 12/13 cases of fatal PE occurred in patients given prophylaxic anticoagulants.<BR/>
<BR/>Regarding the reference to the data on the association between fatal PE and omission of prophylaxis from the Bispebjerg Hospital, University of Copenhagen, Denmark,5 despite the statistical significance of the data (p &lt; .05), little can be concluded from an observational study with 20 cases of post operative fatal PE out of 4881 surgeries. The abstract of this study states, ?Antithrombotic prophylaxis was applied routinely according to standard instructions.? At least some of those not given antithrombotic prophylaxis may have had contraindications.<BR/>
<BR/>In a much larger study of autopsy verified fatal PE cases of all surgical patients in Malmo, Sweden, during the period from 1951 to 1988 in whom pulmonary emboli were found at autopsy (391 cases),6 the incidence of previous prophylaxis with anticoagulants in people with autopsy-proven FPE increased from 50% in 1971-1975 to 76% in 1976-1980, 85% in 1979-1983, and 94% in 1984-1988. The overall incidence of venous thromboembolism in this hospital had not changed from 1957 to 1987.7 Again, these data suggest the possibility of rebound hypercoagulability causing FPE.<BR/>
<BR/>While methodologically correct for its time, the ?International Multicentre Trial?8 was before the era of early mobilization and mechanical VTE prophylaxis. The followup period was only until discharge from hospital, so the deaths due to rebound hypercoagulation on stopping the heparin were missed.<BR/>
<BR/>
<BR/>1. Kakkar VV. Fibrinogen Uptake Test for Detection of Deep Vein Thrombosis - A review of Current Practice. Sem Nucl Med. 1977;7:229-244.<BR/>2. Wille-Jorgensen P, Jorgensen LN, Crawford M. Asymptomatic postoperative deep vein thrombosis and the development of postthrombotic syndrome. A systematic review and meta-analysis. Thromb Haemost. 2005;93(2):236-241.<BR/>3. Hull RD, Pineo GF, Stein PD, et al. Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty: A Systematic Review. Ann Intern Med. 2001;135:858-869.<BR/>4. Goldhaber SZ, Dunn K, MacDougall RC. New Onset of Venous Thromboembolism Among Hospitalized Patients at Brigham and Women?s Hospital Is Caused More Often by Prophylaxis Failure Than by Withholding Treatment. Chest. 2000;118:1680-1684.<BR/>5. Rasmussen MS, Wille-Jorgensen P, Jorgensen LN. Postoperative fatal pulmonary embolism in a general surgical department. Am J Surg. 1995;169(2):214-216.<BR/>6. Lindblad B, Eriksson A, Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. British Journal of Surgery. 1991;78(7):849-852.<BR/>7. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ. 1991;302(6778):709-711.<BR/>8. Kakkar VV, Corrigan TP, Fossard DP, Sutherland I, Thirwell J. Prevention of Fatal Postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. Lancet. 1977;1(8011):567-569.<BR/>
<BR/>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2008-07-24 16:08:52 +0200" MODIFIED_BY="[Empty name]">
<P>"David Cundiff might be correct that a rebound effect exsists after stop of heparin for prophylaxis, but it is still theoretically and based on non-solid epidemiological data only. We still belive that the evidence for using heparin - also in prolonged prophylaxis is owerwhelming".<BR/>
<BR/>on behalf of the authors<BR/>
<BR/>Peer Wille-Jørgensen<BR/>Consultant Surgeon<BR/>Department of Surgery K<BR/>Bispebjerg Hospital,<BR/>DK-2400 Copenhagen NV<BR/>telf: +45 3531 3086<BR/>
</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2008-07-24 16:09:13 +0200" MODIFIED_BY="[Empty name]">
<P>David Cundiff and Peer Wille-Jørgensen</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>